<SEC-DOCUMENT>0000947871-20-000499.txt : 20200519
<SEC-HEADER>0000947871-20-000499.hdr.sgml : 20200519
<ACCEPTANCE-DATETIME>20200519165135
ACCESSION NUMBER:		0000947871-20-000499
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20200519
DATE AS OF CHANGE:		20200519
EFFECTIVENESS DATE:		20200519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-238507
		FILM NUMBER:		20894395

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>ss173456-s8.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As filed with the Securities and Exchange
Commission on May 19, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><B>Registration No. 333-______</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: center">FORM S-8<BR>
REGISTRATION STATEMENT<BR>
UNDER THE SECURITIES ACT OF 1933</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: center"><FONT STYLE="font-size: 16pt">CVS
HEALTH CORPORATION</FONT><FONT STYLE="font-size: 20pt"><BR>
</FONT><FONT STYLE="font-weight: normal">(Exact name of registrant as specified in its charter)</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD>
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>05-0494040</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt">(State or other jurisdiction of</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt">(I.R.S. Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt">incorporation or organization)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">One CVS Drive<BR>
Woonsocket, RI 02895<BR>
(401) 765-1500<BR>
<FONT STYLE="font-size: 8pt; font-weight: normal">(Address including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s
Principal Executive Offices) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white"><B>CVS
HEALTH CORPORATION 2007 EMPLOYEE STOCK PURCHASE PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CVS HEALTH CORPORATION 2017 INCENTIVE COMPENSATION
PLAN</B></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-weight: normal">(Full
title of the plans</FONT>)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">Eva C. Boratto<BR>
<FONT STYLE="background-color: white">Executive Vice President and Chief Financial Officer</FONT><BR>
CVS Health Corporation<BR>
One CVS Drive<BR>
Woonsocket, RI 02895<BR>
(401) 765-1500<BR>
<FONT STYLE="font-size: 8pt; font-weight: normal">(Name, address and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I>With a copy to:</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Doreen E. Lilienfeld, Esq.<BR>
Shearman &amp; Sterling LLP<BR>
599 Lexington Avenue<BR>
New York, NY 10022<BR>
(212) 848-7171</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 4pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;small reporting company,&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt">Large accelerated filer</TD>
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></TD>
    <TD STYLE="width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;</TD>
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">Accelerated filer</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Non-accelerated filer</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Smaller reporting company</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Emerging growth company</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">CALCULATION OF REGISTRATION FEE</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of securities to be registered</B></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Amount to be registered &nbsp;&nbsp;<SUP>(1)(2)</SUP></B></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Proposed maximum offering price per share <SUP>(3)</SUP></B></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Proposed maximum aggregate offering price <SUP>(3)</SUP></B></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Amount of registration fee </B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Common Stock, par value $0.01 per share, each to be issued under the CVS Health Corporation 2007 Employee Stock Purchase Plan</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">30,000,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$61.38</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$1,841,400,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$239,013.72</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Common Stock, par value $0.01 per share, each to be issued under the CVS Health Corporation 2017 Incentive Compensation Plan</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">26,000,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$61.38</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$1,595,880,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">$207,145.22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Total Shares</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">56,000,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&mdash;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: -5.05pt; padding-left: 5.4pt; text-align: center; text-indent: -5.35pt">$3,437,280,000</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.2pt; padding-left: 5.4pt; text-align: center">$446,158.94</TD></TR>
</TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>This Registration Statement on Form S-8 relates to shares of common stock, par value $0.01 per share (&ldquo;<B>Common Stock</B>&rdquo;),
of CVS Health Corporation (the &ldquo;<B>Company</B>&rdquo; or the &ldquo;<B>Registrant</B>&rdquo;) issuable pursuant to the CVS
Health Corporation 2007 Employee Stock Purchase Plan and the CVS Health Corporation 2017 Incentive Compensation Plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
this Registration Statement also covers an indeterminate number of additional shares of Common Stock <FONT STYLE="background-color: white">with
respect to the shares registered hereunder</FONT> in the event of a stock dividend, stock split, or other similar transaction.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Estimated pursuant to Rule 457(h) and Rule 457(c) under the Securities Act, solely for the purpose of computing the registration
fee, based on the average of the high and low prices reported for a share of Common Stock on the New York Stock Exchange on May
14, 2020.</TD></TR></TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>
<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">PART I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The information required by Item 1 and Item 2 of Part I of
Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act of 1933, as amended (the &ldquo;<B>Securities
Act</B>&rdquo;) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will
be delivered to the participants in the plans covered by this Registration Statement as required by Rule 428(b)(1).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">INFORMATION REQUIRED IN THE REGISTRATION
STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 3. Incorporation of Documents by Reference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following documents filed with the Securities and Exchange
Commission (the &ldquo;<B>Commission</B>&rdquo;) by CVS Health Corporation (the &ldquo;<B>Company</B>&rdquo; or the &ldquo;<B>Registrant</B>&rdquo;)
pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;), are incorporated
herein by reference:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 27pt; text-indent: -13.5pt">(a) The Company&rsquo;s Annual
Report on Form 10-K (Registration No. 001-01011) for the fiscal year ended December 31, 2019, filed with the Commission on February
18, 2020, and any amendment thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 27pt; text-indent: -13.5pt">(b) All other reports filed pursuant
to Section 13(a) and 15(d) of the 1934 Act by the Company since the end of the fiscal year covered by the annual report referred
to in (a) above; <I>provided</I>, <I>however</I>, that the foregoing shall not include the incorporation by reference of any information
furnished pursuant to Items 2.02, 7.01 or 9.01 of Form 8-K; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 27pt; text-indent: -13.5pt">(c) The description of the Company&rsquo;s
capital stock contained in the Company&rsquo;s Registration Statement on Form S-4 (No. 333-222412), filed with the Commission on
January 4, 2018, including any amendments or supplements thereto, including Amendment No. 1 filed on January 26, 2018, Amendment
No. 2 filed on February 5, 2018 and Amendment No. 3 filed on February 9, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In addition, all documents subsequently filed by the Company
pursuant to Sections 13(a), 13(c), 14 and 15(d) of the 1934 Act, prior to the filing of a post-effective amendment to this Registration
Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold,
shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing
of such documents. Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that
a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated
by reference herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="background-color: white">With respect to the
unaudited condensed consolidated&nbsp;</FONT>interim<FONT STYLE="background-color: white">&nbsp;financial information of the Company
for the three-month periods ended March&nbsp;31, 2020 and 2019, incorporated by reference in this Registration Statement, Ernst&nbsp;&amp;
Young LLP reported that they have applied limited procedures in accordance with professional standards for a review of such information.
However, their separate report dated May&nbsp;6, 2020, included in the Company&rsquo;s Quarterly Report on&nbsp;Form 10-Q&nbsp;for
the quarter ended March&nbsp;31, 2020, and incorporated by reference herein, states that they did not audit and they do not express
an opinion on that&nbsp;</FONT>interim<FONT STYLE="background-color: white">&nbsp;financial information. Accordingly, the degree
of reliance on their report on such information should be restricted in light of the limited nature of the review procedures applied.
Ernst&nbsp;&amp; Young LLP is not subject to the liability provisions of Section&nbsp;11 of the Securities Act for their report
on the unaudited&nbsp;</FONT>interim<FONT STYLE="background-color: white">&nbsp;financial information because that report is not
a &ldquo;report&rdquo; or a &ldquo;part&rdquo; of the Registration Statement prepared or certified by Ernst&nbsp;&amp; Young LLP
within the meaning of Sections 7 and 11 of the Securities Act.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 4. Description of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Not applicable.</P>
<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 5. Interests of Named Experts and Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 6. Indemnification of Directors and Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Section 102(b)(7) of the Delaware General Corporation Law,
or the DGCL, permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not
be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except
for liability (i) for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (ii) for acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments
of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director
derived an improper personal benefit. The Company&rsquo;s Restated Certificate of Incorporation (the &ldquo;<B>Company Charter</B>&rdquo;)
limits the personal liability of a director to the Company and its stockholders for monetary damages for a breach of fiduciary
duty as a director to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Section 145 of the DGCL provides that a corporation may indemnify
directors and officers as well as other employees and individuals against expenses (including attorneys&rsquo; fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending
or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a
director, officer, employee or agent of the Registrant. The DGCL provides that Section 145 is not exclusive of other rights to
which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors
or otherwise. Expenses, including attorneys&rsquo; fees, incurred by any such person in defending any such action, suit or proceeding
shall be paid or reimbursed by the Company in advance of the final disposition of such action, suit or proceeding upon receipt
by the Company of an undertaking of such person to repay such expenses if it shall ultimately be determined that such person is
not entitled to be indemnified by the Company. The Company Charter provides for indemnification of directors and officers of the
Company against liability they may incur in their capacities as such to the fullest extent permitted under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The directors and officers of the Company are insured under
a policy of directors&rsquo; and officers&rsquo; liability insurance.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 7. Exemption from Registration Claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 8. Exhibits.</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a complete list of exhibits filed as part of this
Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt"><U>Exhibit Number</U></TD>
    <TD STYLE="width: 83%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">3.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518184593/d456958dex31c.htm">Restated Certificate of Incorporation of CVS Health Corporation dated June 4, 2018 (incorporated by reference to Exhibit 3.1C to CVS Health Corporation&rsquo;s Current Report on Form 8-K filed on June 5, 2018; Commission File No. 001-01011).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">3.2</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><A HREF="http://www.sec.gov/Archives/edgar/data/64803/000119312518184593/d456958dex32.htm">By-Laws of CVS Health Corporation, as amended and restated June 4, 2018 (incorporated by reference to Exhibit 3.2 to CVS Health Corporation&rsquo;s Current Report on Form 8-K filed on June 5, 2018; Commission File No. 001-01011).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">5*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><FONT STYLE="background-color: white"><A HREF="ss173456-ex5.htm" STYLE="-sec-extract: exhibit">Opinion of Shearman &amp; Sterling LLP.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">15*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="ss173456-ex15.htm" STYLE="-sec-extract: exhibit">Letter of Acknowledgement from Ernst &amp; Young LLP re: Unaudited&nbsp;Interim&nbsp;Financial Information.</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">23.1*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><A HREF="ss173456-ex2301.htm" STYLE="-sec-extract: exhibit">Consent of Ernst &amp; Young LLP.</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; width: 17%">23.2*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; width: 83%"><A HREF="ss173456-ex5.htm" STYLE="-sec-extract: exhibit">Consent of Shearman &amp; Sterling LLP (contained in the Opinion filed as <U>Exhibit 5</U>).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">24*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><A HREF="ss173456-ex24.htm" STYLE="-sec-extract: exhibit">Power of Attorney.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">99.1*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><FONT STYLE="background-color: white"><A HREF="ss173456-ex9901.htm" STYLE="-sec-extract: exhibit">CVS Health Corporation 2017 Incentive Compensation Plan.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">99.2*</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><FONT STYLE="background-color: white"><A HREF="ss173456-ex9902.htm">CVS Health Corporation 2007 Employee Stock Purchase Plan.</A></FONT></TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Filed herewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Item 9. Undertakings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">(a) The undersigned Registrant hereby
undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 49.5pt">(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in">(i) To include any prospectus required by Section 10(a)(3)
of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in">(ii) To reflect in the prospectus any facts
or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in">(iii) To include any material information
with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such
information in this Registration Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 49.5pt"><I>provided</I>, <I>however</I>, that
paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d)
of the 1934 Act that are incorporated by reference in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 49.5pt">(2) That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I>
offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 49.5pt">(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">(b) The undersigned Registrant hereby
undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual
report pursuant to Section 13(a) or 15(d) of the 1934 Act (and, where applicable, each filing of an employee benefit plan&rsquo;s
annual report pursuant to Section 15(d) of the 1934 Act) that is incorporated by reference in the Registration Statement shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">(c) Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to
the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>
<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Woonsocket, State of Rhode Island, on the 19<SUP>th</SUP> day of May, 2020.</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2">CVS Health Corporation</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>By:</TD><TD STYLE="border-bottom: Black 1pt solid">/s/ Eva C. Boratto</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Name:</TD><TD>Eva C. Boratto</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 252pt"></TD><TD STYLE="width: 31.5pt">Title:</TD><TD>Executive Vice President and<BR>
Chief Financial Officer</TD></TR></TABLE>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0 0 0 279pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0 0 0 279pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to the requirements of the Securities Act of 1933,
as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%">Date: May 19, 2020</TD>
    <TD STYLE="width: 62%; border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Fernando Aguirre</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Eva C. Boratto</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Executive Vice President and Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">C. David Brown II</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">James D. Clark</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Senior Vice President &ndash; Controller and Chief</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Accounting Officer (Principal Accounting Officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Alecia A. DeCoudreaux</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Nancy-Ann M. DeParle</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David W. Dorman</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chair of the Board and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%">Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 62%">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Roger N. Farah</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Anne M. Finucane</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Edward J. Ludgwig</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Larry J. Merlo</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer) and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jean-Pierre Millon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mary L. Schapiro</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">William C. Weldon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 19, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt solid">*</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tony L. White</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P></TD></TR>
</TABLE>
<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">* This Registration Statement has been signed on behalf of
the above officers and directors by Colleen M. McIntosh, as attorney-in-fact pursuant to a power of attorney filed as Exhibit 24
to this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">DATED: May 19, 2020</P>

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0 0 0 279pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Colleen M. McIntosh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 252pt">&nbsp;</TD>
    <TD STYLE="width: 31pt">By:</TD>
    <TD>Colleen M. McIntosh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Attorney-in-Fact</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>2
<FILENAME>ss173456-ex5.htm
<DESCRIPTION>OPINION OF SHEARMAN & STERLING LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 5</B></P>
        <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 9pt; width: 186pt"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 8pt/10pt Arial, Helvetica, Sans-Serif; margin: 4pt 0 0 0; text-align: center">599 Lexington Avenue<BR>
        New York, NY 10022-6069</P>
        <P STYLE="font: 8pt/10pt Arial, Helvetica, Sans-Serif; margin: 0 0 24pt; text-align: center">+1.212.848.4000</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">CVS Health Corporation &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&#9;May 19,
2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">One CVS Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Woonsocket, RI 02895</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">We are acting as counsel for CVS Health Corporation (the &ldquo;<B>Company</B>&rdquo;)
in connection with the preparation and filing by the Company of a registration statement on Form&nbsp;S-8 (the&nbsp;&ldquo;<B>Registration
Statement</B>&rdquo;) with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act
of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), with respect to 30,000,000 shares of common stock, par value $0.01,
of the Company (the&nbsp;&ldquo;<B>Shares</B>&rdquo;) that may be delivered from time to time pursuant to the CVS Health Corporation
2007 Employee Stock Purchase Plan (the &ldquo;<B>ESPP</B>&rdquo;) and 26,000,000 Shares that may be delivered from time to time
pursuant to the CVS Health Corporation 2017 Incentive Compensation Plan (the &ldquo;<B>ICP</B>&rdquo; and, together with ESPP,
the &ldquo;<B>Plans</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">In connection with the foregoing, we have reviewed originals
or copies identified to our satisfaction of the following documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The Registration Statement; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 4.4pt; text-indent: -4.4pt"><FONT STYLE="font-size: 10pt">The certificate of incorporation and by-laws of the Company, in each case as amended to date; and </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Originals or copies of such other corporate records of the Company, certificates of public officials and of officers of the Company, and agreements and other documents as we have deemed necessary as a basis for the opinions expressed below. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">In our examination, we have assumed the genuineness of all
signatures, the authenticity of all documents, certificates and instruments submitted to us as originals, and the conformity with
originals of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Our opinion set forth below is based on the text of the Plans
as referenced in the Exhibit Index to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Our opinion expressed below is limited to the General Corporation
Law of the State of Delaware, and we do not express any opinion herein concerning any other law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Based upon and subject to the foregoing and having regard
for such legal considerations as we have deemed relevant, we are of the opinion that authorized but not previously issued Shares
which may be delivered under the Plans have been duly authorized by the Company and, when (a)&nbsp;issued and delivered by the
Company in accordance with the terms of the Plans and (b)&nbsp;paid for in full in accordance with the terms of the Plans, will
be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">This opinion letter speaks only as of the date hereof. We
expressly disclaim any responsibility to advise you of any development or circumstance of any kind, including any change of law
or fact that may occur after the date of this opinion letter that might affect the opinions expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font: bold 9.5pt Arial Narrow, Helvetica, Sans-Serif">SHEARMAN.COM</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 6pt/8pt Arial, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt">Shearman &amp; Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners.</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We hereby consent to the filing of this opinion as an exhibit to
the Registration Statement. In giving this consent, we do not thereby concede that we come within the category of persons whose
consent is required by the Securities Act or the General Rules and Regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">This opinion is rendered to you in connection with the above
matter. This opinion may not be relied upon by you for any other purpose without our prior written consent.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Shearman&nbsp;&amp; Sterling LLP</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Shearman&nbsp;&amp; Sterling LLP</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>3
<FILENAME>ss173456-ex15.htm
<DESCRIPTION>LETTER OF ACKNOWLEDGEMENT FROM ERNST & YOUNG LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><B>EXHIBIT 15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Acknowledgement Letter re: Unaudited&nbsp;Interim&nbsp;Financial
Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">May&nbsp;19, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">The Board of Directors and Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CVS Health Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">We are aware of the incorporation by
reference in this&nbsp;Registration Statement&nbsp;(Form S-8) of CVS Health
Corporation pertaining to the CVS Health Corporation 2007 Employee Stock Purchase Plan and
the CVS Health Corporation 2017 Incentive Compensation Plan of our report dated May&nbsp;6, 2020, relating to the unaudited condensed
consolidated&nbsp;interim&nbsp;financial statements of CVS Health Corporation that are included in its&nbsp;Form 10-Q&nbsp;for
the quarter ended March&nbsp;31, 2020.</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%">/s/ Ernst&nbsp;&amp; Young LLP</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Boston, Massachusetts</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">May 19, 2020</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ss173456-ex2301.htm
<DESCRIPTION>CONSENT OF ERNST & YOUNG LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><B>EXHIBIT 23.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Consent of Independent Registered
Public Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">We consent to the incorporation by reference in this Registration
Statement (Form S-8) pertaining to the CVS Health Corporation 2007 Employee Stock Purchase Plan and the CVS Health Corporation
2017 Incentive Compensation Plan of our reports dated February 18, 2020<FONT STYLE="font-size: 11pt">,</FONT> with respect to the
consolidated financial statements of CVS Health Corporation and the effectiveness of internal control over  financial reporting
of CVS Health Corporation included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Ernst &amp; Young LLP<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Boston, Massachusetts<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">May 19, 2020</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>5
<FILENAME>ss173456-ex24.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><B>EXHIBIT 24</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints each of Eva C. Boratto and Colleen M. McIntosh as his or her true and lawful attorney-in-fact
and agent, upon the action of either such appointee, with full power of substitution and resubstitution, to do any and all acts
and things and execute, in the name of the undersigned, any and all instruments which each of said attorneys-in-fact and agents
may deem necessary or advisable in order to enable CVS Health Corporation to comply with the Securities Act of 1933, as amended
(the &ldquo;<B>Securities Act</B>&rdquo;), and any requirements of the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act,
including specifically, but without limitation, power and authority to sign the name of the undersigned to such Registration Statement,
and any amendments to such Registration Statement (including post-effective amendments), and to file or cause to be filed the same
with all exhibits thereto and other documents in connection therewith with the Commission, to sign any and all applications, registration
statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file or cause
to be filed the same, together with other documents in connection therewith with the appropriate state securities authorities,
granting unto each of said attorneys-in-fact and agents full power and authority to do and to perform each and every act and thing
requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might
or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents may lawfully do or cause
to be done by virtue of this Power of Attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Pursuant to the requirements of the Securities Act of 1933,
this power of attorney has been signed on this 19<SUP>th</SUP> day of May, 2020 by the following persons in the following capacities.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>Signature</U></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>Title</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Fernando Aguirre</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Fernando Aguirre</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Eva C. Boratto</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Executive Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Eva C. Boratto</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Principal Financial Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ C. David Brown II</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">C. David Brown II</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ James D. Clark</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Senior Vice President &ndash; Controller and Chief</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">James D. Clark</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Accounting Officer (Principal Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Alecia A. DeCoudreaux</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Alecia A. DeCoudreaux</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Nancy-Ann M. DeParle</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Nancy-Ann M. DeParle</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ David W. Dorman</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Chair of the Board and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">David W. Dorman</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Roger N. Farah</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Roger N. Farah</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Anne M. Finucane</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Anne M. Finucane</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Edward J. Ludwig</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Edward J. Ludwig</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 49%">/s/ Larry J. Merlo</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 51%">President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Larry J. Merlo</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Principal Executive Officer) and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Jean-Pierre Millon</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Jean-Pierre Millon</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Mary L. Schapiro</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Mary L. Schapiro</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ William C. Weldon</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">William C. Weldon</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Tony L. White</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Tony L. White</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ss173456-ex9901.htm
<DESCRIPTION>CVS HEALTH CORPORATION 2017 INCENTIVE COMPENSATION PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2017
Incentive Compensation Plan of CVS Health Corporation</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.&nbsp;<I>Purpose</I>.</B>&nbsp;The
purpose of this 2017 Incentive Compensation Plan (the &ldquo;Plan&rdquo;) is to assist CVS Health Corporation, a Delaware corporation
(the &ldquo;Corporation&rdquo;), and its subsidiaries, in attracting, retaining and rewarding high-quality executives, employees,
and other persons who provide services to the Corporation and/or its subsidiaries, to enable such persons to acquire or increase
a proprietary interest in the Corporation in order to strengthen the mutuality of interests between such persons and the Corporation&rsquo;s
stockholders and to provide such persons with short- and long-term performance incentives to expend their maximum efforts in the
creation of stockholder value. The Plan is also intended to qualify certain compensation awarded under the Plan for maximum tax
deductibility under Code Section 162(m) (as hereafter defined) to the extent deemed appropriate by the Committee (or any successor
committee) of the Board of Directors of the Corporation.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.&nbsp;<I>Definitions</I>.</B>&nbsp;For
purposes of the Plan, the following terms shall be defined as set forth below, in addition to such terms defined in Section 1
hereof:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)
&ldquo;Annual Incentive Award&rdquo; means a conditional right granted to a Participant under Section 9(c) hereof to receive a
cash payment, Stock or other Award, unless otherwise determined by the Committee, after the end of a specified fiscal year.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)
&ldquo;Award&rdquo; means any Option, Restricted Stock, Restricted Stock Unit, Stock Appreciation Right, Deferred Stock, Stock
granted as a bonus or in lieu of another award, Stock awarded to a director pursuant to Section 8, Dividend Equivalent, Other
Stock-Based Award, Performance Award or Annual Incentive Award, together with any other right or interest granted to a Participant
under the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)
&ldquo;Beneficiary&rdquo; means the person, persons, trust or trusts which have been designated by a Participant in his or her
most recent written beneficiary designation filed with the Committee to receive the benefits specified under the Plan upon such
Participant&rsquo;s death or to which Awards or other rights are transferred if and to the extent permitted under Section 11(b)
hereof. If, upon a Participant&rsquo;s death, there is no designated Beneficiary or surviving designated Beneficiary, then the
term Beneficiary means person, persons, trust or trusts entitled by will or the laws of descent and distribution to receive such
benefits.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)
&ldquo;Beneficial Owner&rdquo; shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act and any successor
to such Rule.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)
&ldquo;Board&rdquo; means the Corporation&rsquo;s Board of Directors.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(f)
&ldquo;Change in Control&rdquo; means Change in Control as defined with related terms in Section 10 of the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(g)
&ldquo;Code&rdquo; means the Internal Revenue Code of 1986, as amended from time to time, including regulations thereunder and
successor provisions and regulations thereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(h)
&ldquo;Committee&rdquo; means a committee of two or more directors designated by the Board to administer the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
&ldquo;Constructive Termination Without Cause&rdquo; shall have the meaning set forth in Section 10(c)(ii) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(j)
&ldquo;Covered Employee&rdquo; means an Eligible Person who is a Covered Employee as specified in Section 9(e) of the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(k)
&ldquo;Deferred Stock&rdquo; means a right, granted to a Participant under Section 6(e) hereof, to receive Stock, cash or a combination
thereof at the end of a specified deferral period.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(l)
&ldquo;Dividend Equivalent&rdquo; means a right, granted to a Participant under Section 6(g), to receive cash, Stock, other Awards
or other property equal in value to dividends paid with respect to a specified number of shares of Stock, or other periodic payments.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(m)
&ldquo;Eligible Person&rdquo; means each Executive Officer and other officers and employees of the Corporation or of any subsidiary,
including such persons who may also be directors of the Corporation, and any Eligible Director. An employee on leave of absence
may be considered as still in the employ of the Corporation or a subsidiary for purposes of eligibility for participation in the
Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(n)
&ldquo;Eligible Director&rdquo; means a director of the Corporation who at the relevant time is not, and for the preceding twelve
(12) months was not, an employee of the Corporation or its subsidiaries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(o)
&ldquo;Exchange Act&rdquo; means the Securities Exchange Act of 1934, as amended from time to time, including rules thereunder
and successor provisions and rules thereto.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(p)
&ldquo;Executive Officer&rdquo; means an executive officer of the Corporation as defined under the Exchange Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(q)
&ldquo;Fair Market Value&rdquo; means the fair market value of Stock, Awards or other property as determined by the Committee
or under procedures established by the Committee. Unless otherwise determined by the Committee, the Fair Market Value of Stock
shall be the closing price of a share of Stock, as quoted on the composite transactions table on the New York Stock Exchange,
on the date on which the determination of fair market value is being made. In the event the date on which the determination is
being made is a date on which the New York Stock Exchange is closed, then the closing price of a share of Stock, as quoted on
the composite transactions table on the New York Stock Exchange on the last date prior to such date on which the New York Stock
Exchange was open, shall be used.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(r)
&ldquo;Incentive Stock Option&rdquo; or &ldquo;ISO&rdquo; means any Option intended to be and designated as an incentive stock
option within the meaning of Code Section 422 or any successor provision thereto; provided, however, that only an Eligible Person
who is an employee within the meaning of Code Section 422 and the regulations thereunder shall be eligible to receive an ISO.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(s)
&ldquo;Option&rdquo; means a right, granted to a Participant under Section 6(b) hereof, to purchase Stock or other Awards at a
specified price during specified time periods.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(t)
&ldquo;Other Stock-Based Awards&rdquo; means Awards granted to a Participant under Section 6(h) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(u)
&ldquo;Participant&rdquo; means a person who has been granted an Award under the Plan that remains outstanding, including a person
who is no longer an Eligible Person.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(v)
&ldquo;Performance Award&rdquo; means a right, granted to a Participant under Section 9 hereof, to receive Awards based upon performance
criteria specified by the Committee.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(w)
&ldquo;Person&rdquo; shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, and shall include a &ldquo;group&rdquo; as defined in Section 13(d) thereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(x)
&ldquo;Plan Limit&rdquo; means the maximum aggregate number of shares of Stock that may be issued for all purposes under the Plan
as set forth is Section 4(a).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(y)
&ldquo;Qualified Member&rdquo; means a member of the Committee who is a &ldquo;Non-Employee Director&rdquo; within the meaning
of Rule 16b-3(b)(3) and an &ldquo;outside director&rdquo; within the meaning of Regulation 1.162-27 under Code Section 162(m).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(z)
&ldquo;Recoupment Policy&rdquo; means the Recoupment Policy of CVS Health Corporation as amended and restated on May 19, 2016,
as it may be amended from time to time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(aa)
&ldquo;Restricted Stock&rdquo; means Stock granted to a Participant under Section 6(d) hereof, that is subject to certain restrictions
and to a risk of forfeiture.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(bb)
&ldquo;Restricted Stock Unit&rdquo; shall mean a contractual right granted under Section 6(d) hereof that represents a right to
receive the value of a share of Stock upon the terms and conditions set forth in the Plan and the applicable Award agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(cc)
&ldquo;Rule 16b-3&rdquo; means Rule 16b-3, as in effect from time to time and applicable to the Plan and Participants, promulgated
by the Securities and Exchange Commission under Section 16 of the Exchange Act.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(dd)
&ldquo;Stock&rdquo; means the Corporation&rsquo;s Common Stock, and such other securities as may be substituted (or resubstituted)
for Stock pursuant to Section 11(c) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ee)
&ldquo;Stock Appreciation Rights&rdquo; or &ldquo;SAR&rdquo; means a right granted to a Participant under Section 6(c) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ff)
&ldquo;Substitute Award&rdquo; means an Award granted in assumption of, or in substitution for, outstanding awards previously
granted by a company acquired by the Corporation or with which the Corporation combines.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(gg)
&ldquo;Termination Without Cause&rdquo; shall have the meaning set forth in Section 10(c)(i) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.&nbsp;<I>Administration</I>.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Authority
of the Committee</I>. The Plan shall be administered by the Committee, except to the extent the Board elects to administer the
Plan, in which case references herein to the &ldquo;Committee&rdquo; shall be deemed to include references to the &ldquo;Board&rdquo;.
The Committee shall have full and final authority, in each case subject to and consistent with the provisions of the Plan, to
select Eligible Persons to become Participants, grant Awards, determine the type, number and other terms and conditions of, and
all other matters relating to, Awards, prescribe Award agreements (which need not be identical for each Participant) and rules
and regulations for the administration of the Plan, construe and interpret the Plan and Award agreements and correct defects,
supply omissions or reconcile inconsistencies therein and to make all other decisions and determinations as the Committee may
deem necessary or advisable for the administration of the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Manner
of Exercise of Committee Authority</I>. At any time that a member of the Committee is not a Qualified Member, any action of the
Committee relating to an Award granted or to be granted to a Participant who is then subject to Section 16 of the Exchange Act
in respect of the Corporation, or relating to an Award intended by the Committee to qualify as &ldquo;performance-based compensation&rdquo;
within the meaning of Code Section 162(m) and regulations thereunder, may be taken either (i) by a subcommittee, designated by
the Committee, composed solely of two or more Qualified Members, or (ii) by the Committee but with each such member who is not
a Qualified Member abstaining or recusing himself or herself from such action; provided, however, that, upon such abstention or
recusal, the Committee remains composed solely of two or more Qualified Members. Such action, authorized by such a subcommittee
or by the Committee upon the abstention or recusal of such non-Qualified Member(s), shall be the action of the Committee for purposes
of the Plan. Any action of the Committee shall be final, conclusive and binding on all persons, including the Corporation, its
subsidiaries, Participants, Beneficiaries, transferees under Section 11(b) hereof or other persons claiming rights from or through
a Participant, and stockholders. The express grant of any specific power to the Committee, and the taking of any action by the
Committee, shall not be construed as limiting any power or authority of the Committee. To the extent permitted by applicable law,
the Committee may delegate to officers or managers of the Corporation or any subsidiary, or committees thereof, the authority,
subject to such terms as the Committee shall determine, to perform such functions, including administrative functions, as the
Committee may determine, to the extent that such delegation will not result in the loss of an exemption under Rule 16b-3(d)(1)
for Awards granted to Participants subject to Section 16 of the Exchange Act in respect of the Corporation and will not cause
Awards intended to qualify as &ldquo;performance-based compensation&rdquo; under Code Section 162(m) to fail to so qualify. The
Committee may appoint agents to assist it in administering the Plan.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Limitation
of Liability</I>. The Committee and each member thereof shall be entitled to rely or act upon in good faith any report or other
information furnished to him or her by any executive officer, other officer or employee of the Corporation or a subsidiary, the
Corporation&rsquo;s independent auditors, consultants or any other agents assisting in the administration of the Plan. Members
of the Committee and any officer or employee of the Corporation or a subsidiary acting at the direction or on behalf of the Committee
shall not be personally liable for any action or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">determination taken or made in good faith with respect to the Plan and shall,
to the extent permitted by law, be fully indemnified and protected by the Corporation with respect to any such action or determination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>4.&nbsp;<I>Stock
Subject to Plan</I>.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Overall
Number of Shares Available for Delivery</I>.&nbsp;Subject to adjustment as provided in Section 11(c) hereof, the total number
of shares of Stock reserved and available for delivery in connection with Awards under the Plan shall be equal to: (i)&nbsp;forty-seven
million (47,000,000); plus (ii) such additional number of shares of Stock reserved for issuance under the Corporation&rsquo;s
2010 Incentive Compensation Plan, as amended on January 15, 2013 (the &ldquo;Existing Plan&rdquo;) that remain available for grant
under the Existing Plan immediately prior to the Corporation&rsquo;s 2017 Annual Meeting of Stockholders; provided, however, that
the total number of shares of Stock with respect to which ISOs may be granted under the Plan shall not exceed three million (3,000,000).
Any shares of Stock delivered under the Plan shall consist of authorized and unissued shares or treasury shares. Following approval
of the Plan by the Corporation&rsquo;s stockholders, the Existing Plan shall be retired and no further awards shall be granted
from the Existing Plan; provided, however, that awards previously granted under the Existing Plan shall continue to be governed
by the terms of the Existing Plan and any agreements pertaining to those awards.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Application
of Limitation to Grants of Awards</I>. No Award may be granted if the number of shares of Stock to be delivered in connection
with such Award exceeds the number of shares of Stock remaining available under the Plan after taking into account the number
of shares issuable in settlement of Awards or relating to then-outstanding Awards. Notwithstanding the foregoing, Awards settleable
only in cash shall not reduce the number of shares of Stock available under the Plan and Stock issued for Substitute Awards shall
not count against the limits of Section 4(a). Additionally, for purposes of determining the number of shares of Stock that remain
available for issuance under the Plan, the number of shares of Stock corresponding to Awards under the Plan that are forfeited
or cancelled or otherwise expire for any reason without having been exercised or settled, or that are settled through the issuance
of consideration other than shares of Stock (including, without limitation, cash), shall be added back to the Plan Limit and again
be available for the grant of Awards. The following shares of Stock, however, shall not be available again for grant under the
Plan:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
shares of Stock not issued or delivered as a result of net settlement of an outstanding Option or SAR;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
shares of Stock delivered or withheld by the Corporation to pay the exercise price of or the withholding taxes with respect to
an Award; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)
shares of Stock repurchased with proceeds from the payment of the exercise price of an Option.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Committee has discretion to adopt reasonable counting procedures to ensure appropriate counting, avoid double counting (as, for
example, in the case of tandem or substitute awards) and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">make adjustments if the number of shares of Stock actually delivered
differs from the number of shares previously counted in connection with an Award.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>5.&nbsp;<I>Eligibility;
Per-Person Award Limitations</I>.</B>&nbsp;Awards may be granted under the Plan only to Eligible Persons. In each fiscal year
during any part of which the Plan is in effect, an Eligible Person may not be granted Awards relating to more than one million
(1,000,000) shares of Stock, subject to adjustment as provided in Section 11(c), under each of Sections 6(b) through 6(h), 9(b)
and 9(c). In addition, the maximum cash amount that may be earned under the Plan as a final Annual Incentive Award or other cash
annual Award in respect of any fiscal year by any one Participant shall be ten million dollars ($10,000,000), and the maximum
cash amount that may be earned under the Plan as a final Performance Award or other cash Award in respect of a performance period
other than an annual period by any one Participant on an annualized basis shall be five million dollars ($5,000,000).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>6.&nbsp;<I>Specific
Terms of Awards.</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>General.&nbsp;</I>Awards
may be granted on the terms and conditions set forth in this Section 6, and with respect to directors of the Corporation, in Section
8. In addition, the Committee may impose on any Award or the exercise thereof, at the date of grant or thereafter (subject to
Section 11(e)), such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall
determine, including terms requiring forfeiture of Awards in the event of termination of employment of the Participant and terms
permitting a Participant to make elections relating to his or her Award. The Committee shall retain full power and discretion
to accelerate, waive or modify, at any time, any term or condition of an Award that is not mandatory under the Plan. Except in
cases in which the Committee is authorized to require other forms of consideration under the Plan, or to the extent other forms
of consideration must be paid to satisfy the requirements of the Delaware General Corporation Law, no consideration other than
services may be required for the grant of any Award.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Options.&nbsp;</I>The
Committee is authorized to grant Options to Participants on the following terms and conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Exercise
Price</I>.&nbsp;The exercise price per share of Stock purchasable under an Option shall be determined by the Committee, provided
that such exercise price shall be not less than the Fair Market Value of a share of Stock on the date of grant of such Option
except as provided under the first sentence of Section 7(a) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Time
and Method of Exerc</I>ise.&nbsp;The Committee shall determine the time or times at which or the circumstances under which an
Option may be exercised in whole or in part (including based on achievement of performance goals and/or future service requirements),
the methods by which such exercise price may be paid or deemed to be paid, the form of such payment, including, without limitation,
cash, Stock, other Awards or awards granted under other plans of the Corporation or any subsidiary, or other property, and the
methods by or forms in which Stock will be delivered or deemed to be delivered to Participants.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)&nbsp;<I>ISOs</I>.&nbsp;The
terms of any ISO granted under the Plan shall comply in all respects with the provisions of Code Section 422. Anything in the
Plan to the contrary notwithstanding, no term of the Plan relating to ISOs shall be interpreted, amended or altered, nor shall
any discretion or authority granted under the Plan be exercised, so as to disqualify either the Plan or any ISO under Code Section
422, unless the Participant has first requested the change that will result in such disqualification.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Stock
Appreciation Rights</I>.&nbsp;The Committee is authorized to grant SARs to Participants on the following terms and conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Right
to Payment</I>.&nbsp;A SAR shall confer on the Participant to whom it is granted a right to receive, upon exercise thereof, the
excess of (A) the Fair Market Value of one share of Stock on the date of exercise over (B) the grant price of the SAR as determined
by the Committee.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Other
Terms</I>.&nbsp;The Committee shall determine at the date of grant or thereafter, the time or times at which and the circumstances
under which a SAR may be exercised in whole or in part (including based on achievement of performance goals and/or future service
requirements), the method of exercise, method of settlement, form of consideration payable in settlement, method by or forms in
which Stock will be delivered or deemed to be delivered to Participants, whether or not a SAR shall be in tandem or in combination
with any other Award and any other terms and conditions of any SAR. The exercise price of a SAR shall be determined by the Committee,
provided that such exercise price shall be not less than the Fair Market Value of a share of Stock on the date of grant of such
SAR. SARs may be either freestanding or in tandem with other Awards.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)&nbsp;<I>Restricted
Stock and Restricted Stock Units</I>.&nbsp;The Committee is authorized to grant Restricted Stock or Restricted Stock Units to
Participants on the following terms and conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)<I>&nbsp;Grant
and Restrictions</I>.&nbsp;Restricted Stock and Restricted Stock Units shall be subject to such restrictions on transferability,
risk of forfeiture and other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in
combination at such times, under such circumstances (including based on achievement of performance goals and/or future service
requirements), in such installments or otherwise, as the Committee may determine at the date of grant or thereafter. Except to
the extent restricted under the terms of the Plan and any Award agreement relating to the Restricted Stock, a Participant granted
Restricted Stock shall have all of the rights of a stockholder, including the right to vote the Restricted Stock and the right
to receive dividends thereon, provided that dividends shall accrue and be paid only upon vesting, and may be subject to any mandatory
reinvestment or any other requirement that may imposed by the Committee. During the restricted period applicable to the Restricted
Stock, subject to Section 11(b) below, the Restricted Stock may not be sold, transferred, pledged, hypothecated, margined or otherwise
encumbered by the Participant. Restricted Stock Units may be settled in Stock, cash equal to the Fair Market Value of the specified
number of shares of Stock covered by the Units, or a combination thereof, as determined by the Committee at the date of grant
or thereafter.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Forfeiture</I>.&nbsp;Except
as otherwise determined by the Committee, upon termination of employment during the applicable restriction period, Restricted
Stock and Restricted Stock Units that are at that time subject to restrictions shall be forfeited, provided that the Committee
may provide, by rule or regulation or in any Award agreement, or may determine in any individual case, that restrictions or forfeiture
conditions relating to Restricted Stock and Restricted Stock Units shall be waived in whole or in part in the event of terminations
resulting from specified causes and the Committee may in other cases waive in whole or in part the forfeiture of Restricted Stock
and Restricted Stock Units.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)&nbsp;<I>Certificates
for Stock</I>.&nbsp;Restricted Stock granted under the Plan may be evidenced in such manner as the Committee shall determine.
If certificates representing Restricted Stock are registered in the name of the Participant, the Committee may require that such
certificates bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Restricted Stock,
that the Corporation retain physical possession of the certificates and that the Participant deliver a stock power to the Corporation,
endorsed in blank, relating to the Restricted Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)&nbsp;<I>Dividends
and Splits</I>.&nbsp;As a condition to the grant of an Award of Restricted Stock, the Committee may require that any cash dividends
paid on a share of Restricted Stock be automatically reinvested in additional shares of Restricted Stock or applied to the purchase
of additional Awards under the Plan, or shall require vesting of an Award prior to payment of accrued cash dividends. Unless otherwise
determined by the Committee, Stock distributed in connection with a Stock split or Stock dividend, and other property distributed
as a dividend, shall be subject to restrictions and a risk of forfeiture to the same extent as the Restricted Stock with respect
to which such Stock or other property has been distributed. The Committee shall determine and specify in the Restricted Stock
Unit Agreement the effect, if any, of dividends paid on Stock during the period such Award is outstanding.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)&nbsp;<I>Deferred
Stock</I>.&nbsp;The Committee is authorized to grant Deferred Stock to Participants, which are rights to receive Stock, cash,
or a combination thereof at the end of a specified deferral period, subject to the following terms and conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Award
and Restrictions</I>.&nbsp;Satisfaction of an Award of Deferred Stock shall occur upon expiration of the deferral period specified
for such Deferred Stock by the Committee (or, if permitted by the Committee, as elected by the Participant). In addition, Deferred
Stock shall be subject to such restrictions (which may include a risk of forfeiture) as the Committee may impose, if any, which
restrictions may lapse at the expiration of the deferral period or at earlier specified times (including based on achievement
of performance goals and/or future service requirements), separately or in combination, in installments or otherwise, as the Committee
may determine. Deferred Stock may be satisfied by delivery of Stock, cash equal to the Fair Market Value of the specified number
of shares of Stock covered by the Deferred Stock, or a combination thereof, as determined by the Committee at the date of grant
or thereafter.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Forfeiture</I>.&nbsp;Except
as otherwise determined by the Committee, upon termination of employment during the applicable deferral period or portion thereof
to which forfeiture conditions apply (as provided in the Award agreement evidencing the Deferred Stock), all</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">Deferred Stock that
is at that time subject to deferral (other than a deferral at the election of the Participant) shall be forfeited; provided that
the Committee may provide, by rule or regulation or in any Award agreement, or may determine in any individual case, that restrictions
or forfeiture conditions relating to Deferred Stock shall be waived in whole or in part in the event of terminations resulting
from specified causes, and the Committee may in other cases waive in whole or in part the forfeiture of Deferred Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)&nbsp;<I>Dividend
Equivalents</I>.&nbsp;Unless otherwise determined by the Committee at date of grant, Dividend Equivalents on the specified number
of shares of Stock covered by an Award of Deferred Stock shall be either (A) paid with respect to such Deferred Stock at the dividend
payment date in cash or in shares of unrestricted Stock having a Fair Market Value equal to the amount of such dividends, or (B)
deferred with respect to such Deferred Stock and the amount or value thereof automatically deemed reinvested in additional Deferred
Stock, other Awards or other investment vehicles, as the Committee shall determine or permit the Participant to elect.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(f)&nbsp;<I>Bonus
Stock and Awards in Lieu of Obligations</I>.&nbsp;The Committee is authorized to grant Stock as a bonus, or to grant Stock or
other Awards in lieu of obligations to pay cash or deliver other property under the Plan or under other plans or compensatory
arrangements, provided that, in the case of Participants subject to Section 16 of the Exchange Act, the amount of such grants
remains within the discretion of the Committee to the extent necessary to ensure that acquisitions of Stock or other Awards are
exempt from liability under Section 16(b) of the Exchange Act. Stock or Awards granted hereunder shall be subject to such other
terms as shall be determined by the Committee. In the case of any grant of Stock to an officer of the Corporation in lieu of salary
or other cash compensation, the number of shares granted in place of such compensation shall be reasonable, as determined by the
Committee.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(g)&nbsp;<I>Dividend
Equivalents</I>. Except with respect to Options and SARs, which shall not be eligible for Dividend Equivalents, the Committee
is authorized to grant Dividend Equivalents to a Participant, entitling the Participant to receive cash, Stock, other Awards,
or other property equal in value to dividends paid with respect to a specified number of shares of Stock, or other periodic payments.
The Committee shall provide that Dividend Equivalents either shall accrue and be paid or distributed upon the vesting of an Award
or shall be deemed to have been reinvested in additional Stock, Awards, or other investment vehicles and subject to such restrictions
on transferability and risks of forfeiture as the Committee may specify.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(h)&nbsp;<I>Other
Stock-Based or Cash Awards</I>. The Committee is authorized, subject to limitations under applicable law, to grant to Participants
such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or
related to, Stock, as deemed by the Committee to be consistent with the purposes of the Plan, including, without limitation, convertible
or exchangeable debt securities, other rights convertible or exchangeable into Stock, purchase rights for Stock, Awards with value
and payment contingent upon performance of the Corporation or any other factors designated by the Committee and Awards valued
by reference to the book value of Stock or the value of securities of or the performance of specified subsidiaries. The Committee
shall determine the terms and conditions of such Awards. Stock delivered pursuant to an Award in the nature of a purchase right
granted under this Section 6(h) shall be purchased</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">for such consideration, paid for at such times, by such methods, and in such
forms, including, without limitation, cash, Stock, other Awards, or other property, as the Committee shall determine. Cash awards,
as an element of or supplement to any other Award under the Plan, may also be granted pursuant to this Section 6(h).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>7.&nbsp;<I>Certain
Provisions Applicable to Awards.</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Stand-Alone,
Additional, Tandem and Substitute Awards</I>.&nbsp;Awards granted under the Plan may, in the discretion of the Committee, be granted
at any time, either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award
granted under another plan of the Corporation, any subsidiary, or any business entity to be acquired by the Corporation or a subsidiary,
or any other right of a Participant to receive payment from the Corporation or any subsidiary, but if an Award is granted in substitution
or exchange for another Award or award, the Committee shall require the surrender of such other Award or award in consideration
for the grant of the new Award. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash amounts
payable under other plans of the Corporation or any subsidiary, in which the value of Stock subject to the Award (for example,
Deferred Stock or Restricted Stock) is equivalent in value to the cash compensation, provided, however, that any such Award that
is an Option or SAR shall have an exercise price that is at least one hundred percent (100%) of the Fair Market Value of a share
of Stock on the date of grant of such Option or SAR. Notwithstanding the foregoing language of this Section 7(a), no outstanding
Option or SAR may be amended to decrease the exercise price except in accordance with Section 11(c), and no outstanding Option
or SAR may be surrendered in exchange for another Award or for cash.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Term
of Awards</I>.&nbsp;The term of each Award shall be for such period as may be determined by the Committee; provided that in no
event shall the term of any Option or SAR exceed a period of ten (10) years (or such shorter term as may be required in respect
of an ISO under Code Section 422).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Form
and Timing of Payment under Awards; Deferrals</I>.&nbsp;Subject to the terms of the Plan, including but not limited to Section
11(l), and any applicable Award agreement, (i) payments to be made by the Corporation or a subsidiary upon the exercise of an
Option or other Award or settlement of an Award may be made in such forms as the Committee shall determine, including, without
limitation, cash, Stock, other Awards or other property, and may be made in a single payment or transfer, in installments, or
on a deferred basis, (ii) the settlement of any Award may be accelerated, and cash paid in lieu of Stock in connection with such
settlement, in the discretion of the Committee or upon occurrence of one or more specified events (in addition to a Change in
Control), (iii) installment or deferred payments may be required by the Committee (subject to Section 11(e) of the Plan, including
the consent provisions thereof in the case of any deferral of an outstanding Award not provided for in the original Award agreement)
or permitted at the election of the Participant on terms and conditions established by the Committee, and (iv) payments may include,
without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the
grant or crediting of Dividend Equivalents or other amounts in respect of installment or deferred payments denominated in Stock.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)&nbsp;<I>Exemptions
from Section 16(b) Liability</I>.&nbsp;It is the intent of the Corporation that the grant of any Awards to or other transaction
by a Participant who is subject to Section 16 of the Exchange Act</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">shall be exempt under Rule 16b-3 (except for transactions acknowledged
in writing to be non-exempt by such Participant). Accordingly, if any provision of this Plan or any Award agreement does not comply
with the requirements of Rule 16b-3 as then applicable to any such transaction, such provision shall be construed or deemed amended
to the extent necessary to conform to the applicable requirements of Rule 16b-3 so that such Participant shall avoid liability
under Section 16(b).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)&nbsp;<I>Cancellation
and Rescission of Awards</I>.&nbsp;Unless the Award agreement specifies otherwise, the Committee may cancel any unexpired, unpaid,
or deferred Awards at any time, and the Corporation shall have the additional rights set forth in Section 7(e)(iv) below, if the
Participant is not in compliance with all applicable provisions of the Award agreement and the Plan including the following conditions:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
While employed by the Corporation or one of its subsidiaries, a Participant shall not render services for any organization or
engage directly or indirectly in any business that, in the judgment of the Chief Executive Officer of the Corporation or other
senior officer designated by the Committee, is or becomes competitive with the Corporation.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
A Participant shall not, without prior written authorization from the Corporation, disclose to anyone outside the Corporation,
or use in other than the Corporation&rsquo;s business, any confidential information or material relating to the business of the
Corporation that is acquired by the Participant either during or after employment with the Corporation.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)
A Participant shall disclose promptly and assign to the Corporation all right, title, and interest in any invention or idea, patentable
or not, made or conceived by the Participant during employment by the Corporation, relating in any manner to the actual or anticipated
business, research or development work of the Corporation and shall do anything reasonably necessary to enable the Corporation
to secure a patent where appropriate in the United States and in foreign countries.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)
(A) Upon exercise, settlement, payment or delivery pursuant to an Award, the Participant shall certify on a form acceptable to
the Committee that he or she is in compliance with the terms and conditions of the Plan. Failure to comply with the provisions
of this Section 7(e) prior to, or during the six (6) months after, any exercise, payment or delivery pursuant to an Award shall
cause such exercise, payment or delivery to be rescinded. The Corporation shall notify the Participant in writing of any such
rescission within two (2) years after such exercise, payment or delivery. Within ten (10) days after receiving such a notice from
the Corporation, the Participant shall pay to the Corporation the amount of any gain realized or payment received as a result
of the rescinded exercise, payment or delivery pursuant to an Award. Such payment shall be made either in cash or by returning
to the Corporation the number of shares of Stock that the Participant received in connection with the rescinded exercise, payment
or delivery.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(B)
To the extent determined by the Committee, all Awards shall be subject to the terms and conditions of the Corporation&rsquo;s
Recoupment Policy as it exists from time to time.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(f)<I>&nbsp;Limitation
of Vesting of Certain Awards.</I>&nbsp;Notwithstanding anything in this Plan to the contrary, Options, SARs, Restricted Stock,
Restricted Stock Units, Deferred Stock, Dividend Equivalents and Other Stock-Based Awards, as described in Sections 6(b), 6(c),
6(d), 6(e), 6(g) and 6(h) of the Plan, respectively, granted to employees, and Awards granted to directors as described in Section
8 of the Plan, will vest over a minimum period of three (3) years, except in the event of a Participant&rsquo;s death or disability,
or in the event of a Change in Control and (i) Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock, Dividend
Equivalents and Other Stock-Based Awards as to which either the grant or the vesting is based on the achievement of one or more
performance conditions will vest over a minimum period of one (1) year except in the event of a Participant&rsquo;s death or disability,
or in the event of a Change in Control, and (ii) up to five percent (5%) of the shares of Stock authorized under the Plan may
be granted as Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock, Dividend Equivalents or Other Stock-Based
Awards without any minimum vesting requirements. For purposes of this Section 7(f), vesting over a three (3)-year period will
include periodic vesting over such period if the rate of such vesting is proportional throughout such period and in no event shall
Awards subject to a minimum vesting period vest any earlier than one (1) year from the date of grant.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>8.&nbsp;<I>Special
Rules for Directors.</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)<I>&nbsp;Awards;
Per-Director Award Limitation</I>.&nbsp;Eligible Directors may receive Awards, including without limitation Awards in respect
of their annual retainer and any additional retainers for chairing the board or a committee of the board, or serving as lead independent
director.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
maximum number of shares of Stock subject to Awards granted under the Plan during any one fiscal year to any one Eligible Director,
taken together with any cash fees paid or Stock otherwise granted by the Company to such Eligible Director during such fiscal
year for service as a non-employee director, will not exceed the following in total value (calculating the value of any such Awards
based on the grant date fair value of such Awards for financial reporting purposes): (i) five hundred thousand dollars ($500,000)
for each Eligible Director, and (ii) an additional five hundred thousand dollars ($500,000) for the Eligible Director designated
as independent chairman of the board or as lead independent director, in each such case including the value of any Awards in Stock
that are received in lieu of all or a portion of any annual board chair, committee chair, or lead independent director cash retainers
or similar cash-based payments and excluding, for this purpose, the value of any dividend equivalent payments paid pursuant to
any Awards granted in a previous year.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Deferral
of Shares by Directors</I>. Each Eligible Director may elect to defer the receipt of shares otherwise currently payable to such
Eligible Director under Section 8(a) of this Plan until such Eligible Director terminates service as a director or such other
date or event as permitted under rules established by the Board and uniformly applied. In that event, such Eligible Director shall
be granted an award of share credits equal to the number of shares of Stock elected to be deferred, including fractional share
credits to not less than three decimal places.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)<I>&nbsp;Settlement</I>.&nbsp;As
soon as practicable after an Eligible Director has ceased being a Director of the Corporation or such other date or event elected
by an Eligible Director under Section 8(b), all awards shall be paid to the Eligible Director or, in the case of the death of
the Eligible Director,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Eligible Director&rsquo;s designated beneficiary or beneficiaries, or in the absence of a designated
beneficiary, to the estate of the Eligible Director, in a single payment or installments as elected by the Eligible Director.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)&nbsp;<I>Dividend
Equivalents</I>.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
In addition to the payment provided for in Section 8(c), each Eligible Director (or beneficiary) entitled to payment under this
Section 8(d) shall receive at the same time the dividend equivalent amounts calculated under subsection (ii) below.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
The dividend equivalent amount is the number of additional share credits attributable to the number of share credits originally
granted plus additional share credits previously calculated hereunder. Such additional share credits shall be determined and credited
as of each dividend payment date by dividing the aggregate cash dividends that would have been paid had share credits awarded
or credited (but not yet paid) under this Section 8(d), as the case may be, been actual shares of Stock on the record date for
such dividend by the Fair Market Value of Stock on the dividend payment date. Fractional share credits shall be calculated to
not less than three decimal places.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)&nbsp;<I>Payment;
Fractional Shares</I>.&nbsp;Payments pursuant to Sections 8(c) and 8(d) above shall be made in shares of Stock, except that there
shall be paid in cash the value of any fractional share.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>9.&nbsp;<I>Performance
and Annual Incentive Awards.</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Performance
Conditions.</I>&nbsp;The right of a Participant to exercise or receive a grant or settlement of any Award, and the timing thereof,
may be subject to such performance conditions as may be specified by the Committee. The Committee may use such business criteria
and other measures of performance as it may deem appropriate in establishing any performance conditions and may exercise its discretion
to reduce or increase the amounts payable under any Award subject to performance conditions, except as limited under Sections
9(b) and 9(c) hereof in the case of a Performance Award or Annual Incentive Award intended to qualify under Code Section 162(m).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Performance
Awards Granted to Designated Covered Employees</I>.&nbsp;If the Committee determines that a Performance Award to be granted to
an Eligible Person who is designated by the Committee as likely to be a Covered Employee should qualify as &ldquo;performance-based
compensation&rdquo; for purposes of Code Section 162(m), the grant, exercise and/or settlement of such Performance Award shall
be contingent upon achievement of pre-established performance goals and other terms set forth in this Section 9(b).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Performance
Goals Generally</I>.&nbsp;The performance goals for such Performance Awards shall consist of one or more business criteria and
a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee consistent with
this Section 9(b). Performance goals shall be objective and shall otherwise meet the requirements of Code Section 162(m) and regulations
thereunder (including Regulation 1.162-27 and successor regulations thereto), including the requirement that the level or levels
of performance targeted by the Committee result in the achievement of performance goals being &ldquo;substantially uncertain.&rdquo;
The</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">Committee may determine that such Performance Awards shall be granted, exercised and/or settled upon achievement of any one
performance goal or that two or more of the performance goals must be achieved as a condition to grant, exercise and/or settlement
of such Performance Awards. Performance goals may differ for Performance Awards granted to any one Participant or to different
Participants.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Business
Criteria</I>.&nbsp;One or more of the following business criteria for the Corporation, on a consolidated basis, and/ or for specified
subsidiaries or business units of the Corporation (except with respect to the total stockholder return and earnings per share
criteria), shall be used by the Committee in establishing performance goals for such Performance Awards: (1) earnings per share;
(2) revenues; (3) cash flow; (4) cash flow return on investment; (5) return on net assets, return on assets, return on investment,
return on capital, return on equity; (6) economic value added; (7) operating margin; (8) Common Knowledge Retail Customer Service
score or a similar customer service measurement as measured by a third-party administrator; (9) Pharmacy Benefit Services Customer
Satisfaction score; (10) net income; pretax earnings; pretax earnings before interest, depreciation and amortization; pretax operating
earnings after interest expense and before incentives, service fees and extraordinary or special items; operating earnings; (11)
total stockholder return; or (12) any of the above goals as compared to the performance of a published or special index deemed
applicable by the Committee including, but not limited to, the Standard &amp; Poor&rsquo;s 500 Stock Index or a group of comparator
companies. One or more of the foregoing business criteria shall also be exclusively used in establishing performance goals for
Annual Incentive Awards granted to a Covered Employee under Section 9(c) hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)<I>&nbsp;Performance
Period; Timing for Establishing Performance Goals</I>.&nbsp;Achievement of performance goals in respect of such Performance Awards
shall be measured over a performance period of at least one (1) year and up to ten (10) years, as specified by the Committee.
Performance goals shall be established not later than ninety (90) days after the beginning of any performance period applicable
to such Performance Awards, or at such other date as may be required or permitted for &ldquo;performance-based compensation&rdquo;
under Code Section 162(m).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)&nbsp;<I>Performance
Award Pool</I>.&nbsp;The Committee may establish a Performance Award pool, which shall be an unfunded pool, for purposes of measuring
performance of the Corporation in connection with Performance Awards. The amount of such Performance Award pool shall be based
upon the achievement of a performance goal or goals based on one or more of the business criteria set forth in Section 9(b)(ii)
hereof during the given performance period, as specified by the Committee in accordance with Section 9(b)(iii) hereof. The Committee
may specify the amount of the Performance Award pool as a percentage of any of such business criteria, a percentage thereof in
excess of a threshold amount, or as another amount that need not bear a strictly mathematical relationship to such business criteria.
The maximum amount payable to any Participant shall be a stated percentage of the pool; provided the sum of such percentages shall
not exceed one hundred percent (100%) and the payment does not exceed the per-person award limit set forth in Section 5.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(v)&nbsp;<I>Settlement
of Performance Awards; Other Terms.</I>&nbsp;Settlement of such Performance Awards shall be in cash, Stock, other Awards or other
property, at the discretion of the Committee. The Committee may, in its discretion, reduce the amount of a settlement otherwise
to be made in connection with such Performance Awards, but may not exercise discretion to increase any such amount payable to
a Covered Employee in respect of a Performance Award subject to this Section 9(b). The Committee shall specify the circumstances
in which such Performance Awards shall be paid or forfeited in the event of termination of employment of the Participant prior
to the end of a performance period or settlement of Performance Awards.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Annual
Incentive Awards Granted to Designated Covered Employees.</I>&nbsp;If the Committee determines that an Annual Incentive Award
to be granted to an Eligible Person who is designated by the Committee as likely to be a Covered Employee should qualify as &ldquo;performance-based
compensation&rdquo; for purposes of Code Section 162(m), the grant, exercise and/or settlement of such Annual Incentive Award
shall be contingent upon achievement of pre-established performance goals and other terms set forth in this Section 9(c).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Annual
Incentive Award Pool.</I>&nbsp;The Committee may establish an Annual Incentive Award pool, which shall be an unfunded pool, for
purposes of measuring performance of the Corporation in connection with Annual Incentive Awards. The amount of such Annual Incentive
Award pool shall be based upon the achievement of a performance goal or goals based on one or more of the business criteria set
forth in Section 9(b)(ii) hereof during the given performance period, as specified by the Committee in accordance with Section
9(b)(iii) hereof. The Committee may specify the amount of the Annual Incentive Award pool as a percentage of any of such business
criteria, a percentage thereof in excess of a threshold amount, or as another amount that need not bear a strictly mathematical
relationship to such business criteria. The maximum amount payable to any Participant shall be a stated percentage of the pool;
provided the sum of such percentages shall not exceed one hundred percent (100%) and the payment does not exceed the per-person
award limit set forth in Section 5.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)&nbsp;<I>Potential
Annual Incentive Awards.</I>&nbsp;Not later than the end of the ninetieth (90th) day of each fiscal year, or at such other date
as may be required or permitted in the case of Awards intended to be &ldquo;performance-based compensation&rdquo; under Code Section
162(m), the Committee shall determine the Eligible Persons who will potentially receive Annual Incentive Awards, and the amounts
potentially payable thereunder, for that fiscal year, either out of an Annual Incentive Award pool established by such date under
Section 9(c)(i) hereof or as individual Annual Incentive Awards. In the case of individual Annual Incentive Awards intended to
qualify under Code Section 162(m), the amount potentially payable shall be based upon the achievement of a performance goal or
goals based on one or more of the business criteria set forth in Section 9(b)(ii) hereof in the given performance year, as specified
by the Committee; in other cases, such amount shall be based on such criteria as shall be established by the Committee. In all
cases, the maximum Annual Incentive Award of any Participant shall be subject to the limitation set forth in Section 5 hereof.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)&nbsp;<I>Payout
of Annual Incentive Awards.</I>&nbsp;After the end of each fiscal year, the Committee shall determine the amount, if any, of (A)
the Annual Incentive Award pool, and the maximum amount of potential Annual Incentive Award payable to each Participant in the
Annual</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">Incentive Award pool, or (B) the amount of potential Annual Incentive Award otherwise payable to each Participant. The
Committee may, in its discretion, determine that the amount payable to any Participant as a final Annual Incentive Award shall
be increased or reduced from the amount of his or her potential Annual Incentive Award, including a determination to make no final
Award whatsoever, but may not exercise discretion to increase any such amount in the case of an Annual Incentive Award intended
to qualify under Code Section 162(m). The Committee shall specify the circumstances in which an Annual Incentive Award shall be
paid or forfeited in the event of termination of employment by the Participant prior to the end of a fiscal year or settlement
of such Annual Incentive Award.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)&nbsp;<I>Written
Determinations</I>. All determinations by the Committee as to the establishment of performance goals, the amount of any Performance
Award pool or potential individual Performance Awards and as to the achievement of performance goals relating to Performance Awards
under Section 9(b), and the amount of any Annual Incentive Award pool or potential individual Annual Incentive Awards and the
amount of final Annual Incentive Awards under Section 9(c), shall be made in writing in the case of any Award intended to qualify
under Code Section 162(m). The Committee may not delegate any responsibility relating to such Performance Awards or Annual Incentive
Awards.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)&nbsp;<I>Status
of Section 9(b) and Section 9(c) Awards under Code Section 162(m).&nbsp;</I>It is the intent of the Corporation that Performance
Awards and Annual Incentive Awards under Sections 9(b) and 9(c) hereof granted to persons who are designated by the Committee
as likely to be Covered Employees within the meaning of Code Section 162(m) and regulations thereunder (including Regulation 1.162-27
and successor regulations thereto) shall, if so designated by the Committee, constitute &ldquo;performance-based compensation&rdquo;
within the meaning of Code Section 162(m) and regulations thereunder. Accordingly, the terms of Sections 9(b) through (e), including
the definitions of Covered Employee and other terms used therein, shall be interpreted in a manner consistent with Code Section
162(m) and regulations thereunder. The foregoing notwithstanding, because the Committee cannot determine with certainty whether
a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered
Employee as used herein shall mean only a person designated by the Committee, at the time of grant of Performance Awards or an
Annual Incentive Award, as likely to be a Covered Employee with respect to that fiscal year. If any provision of the Plan as in
effect on the date of adoption or any agreements relating to Performance Awards or Annual Incentive Awards that are designated
as intended to comply with Code Section 162(m) does not comply or is inconsistent with the requirements of Code Section 162(m)
or regulations thereunder, such provision shall be construed or deemed amended to the extent necessary to conform to such requirements.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>10.&nbsp;Change
in Control.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Effect
of &ldquo;Change in Control&rdquo;.</I>&nbsp;In the event that a Participant experiences a Termination Without Cause or a Constructive
Termination Without Cause within two (2) years following a &ldquo;Change in Control,&rdquo; the following provisions shall apply
unless otherwise provided in the Award agreement:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
Within two (2) years of a Change in Control, any Award carrying a right to exercise that was not previously exercisable and vested
shall become fully exercisable and vested upon a Termination Without Cause or a Constructive Termination Without Cause and shall
remain exercisable and vested for the balance of the stated term of such Award without regard to any termination of employment
by the Participant, subject only to applicable restrictions set forth in Section 11(a) hereof;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
Within two (2) years of a Change in Control, the restrictions, deferral of settlement and forfeiture conditions applicable to
any other Award granted under the Plan shall lapse and such Awards shall be deemed fully vested upon a Termination Without Cause
or a Constructive Termination Without Cause, except to the extent of any waiver by the Participant and subject to applicable restrictions
set forth in Section 11(a) hereof; and</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)
With respect to any outstanding Award subject to achievement of performance goals and conditions under the Plan, such performance
goals and other conditions will be deemed to be met at actual performance or prorated as of the date of termination.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Definition
of &ldquo;Change in Control&rdquo;.&nbsp;</I>A &ldquo;Change in Control&rdquo; shall be deemed to have occurred if:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
any Person (other than (w) the Corporation, (x) any trustee or other fiduciary holding securities under any employee benefit plan
of the Corporation, (y) any corporation owned, directly or indirectly, by the stockholders of the Corporation immediately after
the occurrence with respect to which the evaluation is being made in substantially the same proportions as their ownership of
the common stock of the Corporation immediately prior to such occurrence, or (z) any surviving or resulting entity from a merger
or consolidation referred to in clause (iii) below that does not constitute a Change in Control under clause (iii) below) becomes
the Beneficial Owner (except that a Person shall be deemed to be the Beneficial Owner of all shares that any such Person has the
right to acquire pursuant to any agreement or arrangement or upon exercise of conversion rights, warrants or options or otherwise,
without regard to the sixty (60) day period referred to in Rule 13d-3 under the Exchange Act), as directly or indirectly, of securities
of the Corporation or of any subsidiary owning directly or indirectly all or substantially all of the consolidated assets of the
Corporation (a &ldquo;Significant Subsidiary&rdquo;), representing thirty percent (30%) or more of the combined voting power of
the Corporation&rsquo;s or such Significant Subsidiary&rsquo;s then outstanding securities;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
during any period of twelve (12) consecutive months, individuals who at the beginning of such period constitute the Board, and
any new director whose election by the Board or nomination for election by the Corporation&rsquo;s stockholders was approved by
a vote of at least a majority of the directors then still in office who either were directors at the beginning of the twelve (12)-month
period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a
majority of the Board;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)
the consummation of a merger or consolidation of the Corporation or any Significant Subsidiary with any other entity, other than
a merger or consolidation which would result in the voting securities of the Corporation or a Significant Subsidiary outstanding
immediately</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving or resulting entity) more than fifty percent (50%) of the combined voting power of the surviving or resulting
entity outstanding immediately after such merger or consolidation; or</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)
the consummation of a transaction (or series of transactions within a twelve (12)-month period) which constitutes the sale or
disposition of all or substantially all of the consolidated assets of the Corporation but in no event assets having a gross fair
market value of less than forty percent (40%) of the total gross fair market value of all of the consolidated assets of the Corporation
(other than such a sale or disposition immediately after which such assets will be owned directly or indirectly by the stockholders
of the Corporation in substantially the same proportions as their ownership of the common stock of the Corporation immediately
prior to such sale or disposition.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Definition
of &ldquo;Termination Without Cause&rdquo; and &ldquo;Constructive Termination Without Cause&rdquo;.</I></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)
&ldquo;Termination Without Cause&rdquo; shall mean the involuntary termination of a Participant&rsquo;s employment by the Corporation
or a subsidiary without Cause.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)
&ldquo;Constructive Termination Without Cause&rdquo; shall mean the Participant&rsquo;s termination of his or her employment following
the occurrence, without the Participant&rsquo;s written consent, of one or more of (A) an assignment of any duties to the Participant
that is materially inconsistent with Participant&rsquo;s position, (B) a material decrease in Participant&rsquo;s annual base
salary or target annual incentive award opportunity, or (C) a relocation of Participant&rsquo;s principal place of employment
more than thirty-five (35) miles from Participant&rsquo;s place of employment before such relocation. In all cases, no Constructive
Termination Without Cause shall be deemed to have occurred if any such event occurs as a result of a prior termination. In addition,
no Constructive Termination Without Cause shall be deemed to have occurred unless the Participant provides written notice to the
Corporation that any such event has occurred, which notice identifies the event and is provided within thirty (30) days of the
initial occurrence of such event, a cure period of forty-five (45) days following the Corporation&rsquo;s receipt of such notice
expires and the Corporation has not cured such event within such cure period, and the Participant actually terminates his/her
employment within thirty (30) days of the expiration of the cure period.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 15pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)
&ldquo;Cause&rdquo; shall be deemed to occur if the Participant (A) willfully and materially breaches any of his or her obligations
to the Corporation with respect to confidentiality, cooperation with regard to litigation, non-disparagement and non-solicitation;
(B) is convicted of a felony involving moral turpitude; or (C) engages in conduct that constitutes willful gross neglect or willful
gross misconduct in carrying out Participant&rsquo;s duties to the Corporation, resulting, in either case, in material harm to
the financial condition or reputation of the Corporation.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>11.&nbsp;General
Provisions.</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;<I>Compliance
with Legal and Other Requirements.</I>&nbsp;The Corporation may, to the extent deemed necessary or advisable by the Committee,
postpone the issuance or delivery of Stock or payment</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">of other benefits under any Award until completion of such registration
or qualification of such Stock or other required action under any federal or state law, rule or regulation, listing or other required
action with respect to any stock exchange or automated quotation system upon which the Stock or other securities of the Corporation
are listed or quoted, or compliance with any other obligation of the Corporation, as the Committee may consider appropriate, and
may require any Participant to make such representations, furnish such information and comply with or be subject to such other
conditions as it may consider appropriate in connection with the issuance or delivery of Stock or payment of other benefits in
compliance with applicable laws, rules, and regulations, listing requirements, or other obligations. The foregoing notwithstanding,
in connection with a Change in Control, the Corporation shall take or cause to be taken no action, and shall undertake or permit
to arise no legal or contractual obligation, that results or would result in any postponement of the issuance or delivery of Stock
or payment of benefits under any Award or the imposition of any other conditions on such issuance, delivery or payment, to the
extent that such postponement or other condition would represent a greater burden on a Participant than existed on the ninetieth
(90<SUP>th</SUP>) day preceding the Change in Control.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;<I>Limits
on Transferability; Beneficiaries.&nbsp;</I>No Award or other right or interest of a Participant under the Plan shall be pledged,
hypothecated or otherwise encumbered or subject to any lien, obligation or liability of such Participant to any party (other than
the Corporation or a subsidiary), or assigned or transferred by such Participant otherwise than by will or the laws of descent
and distribution or to a Beneficiary upon the death of a Participant, and such Awards or rights that may be exercisable shall
be exercised during the lifetime of the Participant only by the Participant or his or her guardian or legal representative, except
that Awards and other rights (other than ISOs in tandem therewith) may be transferred (without receipt of value from the transferee)
to one or more Beneficiaries, family members or other permitted transferees designated by the Committee during the lifetime of
the Participant, and may be exercised by such transferees in accordance with the terms of such Award, but only if and to the extent
such transfers are permitted by the Committee pursuant to the express terms of an Award agreement (subject to any terms and conditions
which the Committee may impose thereon). A Beneficiary, transferee, or other person claiming any rights under the Plan from or
through any Participant shall be subject to all terms and conditions of the Plan and any Award agreement applicable to such Participant,
except as otherwise determined by the Committee, and to any additional terms and conditions deemed necessary or appropriate by
the Committee.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(c)&nbsp;<I>Adjustments.&nbsp;</I>In
the event that any dividend or other distribution (whether in the form of cash, Stock, or other property), recapitalization, forward
or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange, liquidation, dissolution
or other similar corporate transaction or event affects the Stock such that an adjustment is determined by the Committee to be
appropriate under the Plan, then the Committee shall, in such manner as it may deem equitable, adjust any or all of (i) the number
and kind of shares of Stock which may be delivered in connection with Awards granted thereafter, (ii) the number and kind of shares
of Stock by which annual per-person Award limitations are measured under Section 5 hereof, (iii) the number and kind of shares
of Stock subject to or deliverable in respect of outstanding Awards, and (iv) the exercise price, grant price or purchase price
relating to any Award and/or make provision for payment of cash or other property in respect of any outstanding Award. In addition,
the Committee is authorized to make adjustments in the terms and conditions of, and the criteria</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">included in, Awards (including
Performance Awards and performance goals, and Annual Incentive Awards and any Annual Incentive Award pool or performance goals
relating thereto) in recognition of unusual or nonrecurring events (including, without limitation, events described in the preceding
sentence, as well as acquisitions and dispositions of businesses and assets) affecting the Corporation, any subsidiary or any
business unit, or the financial statements of the Corporation or any subsidiary, or in response to changes in applicable laws,
regulations, accounting principles, tax rates and regulations or business conditions or in view of the Committee&rsquo;s assessment
of the business strategy of the Corporation, any subsidiary or business unit thereof, performance of comparable organizations,
economic and business conditions, personal performance of a Participant, and any other circumstances deemed relevant; provided
that no such adjustment shall be authorized or made if and to the extent that such authority or the making of such adjustment
would cause Performance Awards granted under Section 9(b) hereof or Annual Incentive Awards granted under Section 9(c) hereof
to Participants designated by the Committee as Covered Employees and intended to qualify as &ldquo;performance-based compensation&rdquo;
under Code Section 162(m) and regulations thereunder to otherwise fail to qualify as &ldquo;performance-based compensation&rdquo;
under Code Section 162(m) and regulations thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(d)&nbsp;<I>Taxes.&nbsp;</I>The
Corporation and any subsidiary is authorized to withhold from any Award granted, any payment relating to an Award under the Plan,
including from a distribution of Stock, or any payroll or other payment to a Participant, amounts of withholding and other taxes
required to be withheld by the applicable employment tax rules in connection with any transaction involving an Award, and to take
such other action as the Committee may deem advisable to enable the Corporation to satisfy obligations for the payment of withholding
taxes relating to any Award. To the extent permitted by applicable law, the Committee shall be entitled to deduct and withhold
additional amounts so long as such additional deductions would not cause an Award classified as equity under applicable accounting
principles and standards to be classified as a liability award under such principles and standards. The Committee&rsquo;s authority
shall also include authority to withhold or receive Stock or other property and to make cash payments in respect thereof in satisfaction
of such withholding tax obligations.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(e)&nbsp;<I>Changes
to the Plan and Awards.&nbsp;</I>The Board may amend, alter, suspend, discontinue or terminate the Plan or the Committee&rsquo;s
authority to grant Awards under the Plan without the consent of stockholders or Participants, except that any amendment or alteration
to the Plan shall be subject to the approval of the Corporation&rsquo;s stockholders not later than the annual meeting next following
such Board action if such stockholder approval is required by any federal or state law or regulation or the rules of any stock
exchange or automated quotation system on which the Stock may then be listed or quoted, or if the amendment increases the number
of shares of Stock reserved and available for delivery in connection with Awards, materially modifies the requirements as to eligibility
for participation in the Plan, or materially increases the benefits accruing to Participants, and the Board may otherwise, in
its discretion, determine to submit other such changes to the Plan to stockholders for approval; provided that, without the consent
of an affected Participant, no such Board action may materially and adversely affect the rights of such Participant under any
previously granted and outstanding Award, except to the extent the Committee considers such amendment necessary or advisable to
comply with any law, regulation, ruling, judicial decision, accounting standards, regulatory guidance or other legal requirement.
Subject to the provisions of Section 7(a) the Committee may waive any conditions or rights under, or amend, alter, suspend,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">discontinue
or terminate any Award theretofore granted and any Award agreement relating thereto, except as otherwise provided in the Plan;
provided that, without the consent of an affected Participant, no such Committee action may materially and adversely affect the
rights of such Participant under such Award.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(f)&nbsp;<I>Limitation
on Rights Conferred under Plan.&nbsp;</I>Neither the Plan nor any action taken hereunder shall be construed as (i) giving any
Eligible Person or Participant the right to continue as an Eligible Person or Participant or in the employ or service of the Corporation
or a subsidiary, (ii) interfering in any way with the right of the Corporation or a subsidiary to terminate any Eligible Person&rsquo;s
or Participant&rsquo;s employment or service at any time, (iii) giving an Eligible Person or Participant any claim to be granted
any Award under the Plan or to be treated uniformly with other Participants and employees, or (iv) conferring on a Participant
any of the rights of a stockholder of the Corporation unless and until the Participant is duly issued or transferred shares of
Stock in accordance with the terms of an Award.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(g)&nbsp;<I>Unfunded
Status of Awards; Creation of Trusts.&nbsp;</I>The Plan is intended to constitute an &ldquo;unfunded&rdquo; plan for incentive
and deferred compensation. With respect to any payments not yet made to a Participant or obligation to deliver Stock pursuant
to an Award, nothing contained in the Plan or any Award shall give any such Participant any rights that are greater than those
of a general creditor of the Corporation; provided that the Committee may authorize the creation of trusts and deposit therein
cash, Stock, other Awards or other property, or make other arrangements to meet the Corporation&rsquo;s obligations under the
Plan. Such trusts or other arrangements shall be consistent with the &ldquo;unfunded&rdquo; status of the Plan unless the Committee
otherwise determines with the consent of each affected Participant. The trustee of such trusts may be authorized to dispose of
trust assets and reinvest the proceeds in alternative investments, subject to such terms and conditions as the Committee may specify
and in accordance with applicable law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(h)&nbsp;<I>Non-exclusivity
of the Plan.&nbsp;</I>Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Corporation
for approval shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other
incentive arrangements as it may deem desirable including incentive arrangements and awards which do not qualify under Code Section
162(m).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(i)&nbsp;<I>Payments
in the Event of Forfeitures; Fractional Shares.&nbsp;</I>Unless otherwise determined by the Committee, in the event of a forfeiture
of an Award with respect to which a Participant paid cash or other consideration, the Participant shall be repaid the amount of
such cash or other consideration. No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Award.
The Committee shall determine whether cash, other Awards or other property shall be issued or paid in lieu of such fractional
shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(j)&nbsp;<I>Governing
Law.&nbsp;</I>The validity, construction and effect of the Plan, any rules and regulations under the Plan, and any Award agreement
shall be determined in accordance with the Delaware General Corporation Law, without giving effect to principles of conflicts
of laws, and applicable federal law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(k)&nbsp;<I>Recoupment.&nbsp;</I>Each
Award under the Plan shall be subject to the terms of the Corporation&rsquo;s Recoupment Policy, and to such other recoupment
policies or provisions as may be required under the terms of any agreement between the Corporation and any regulatory authority
or as may be required under applicable law.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(l)&nbsp;<I>Code
Section 409A.&nbsp;</I>With respect to Awards subject to Code Section 409A, the Plan is intended to comply with the requirements
of Code Section 409A, and the provisions hereof shall be interpreted in a manner that satisfies the requirements of Code Section
409A and the related regulations, and the Plan shall be operated accordingly. If any provision of the Plan or any term or condition
of any Award would otherwise frustrate or conflict with this intent, the provision, term or condition will be interpreted and
deemed amended so as to avoid this conflict. The Committee may not accelerate the payment or settlement of any Award that constitutes
a deferral of compensation for purposes of Code Section 409A except to the extent such acceleration would not result in the Participant
incurring interest or additional tax under Code Section 409A. Notwithstanding anything in the Plan to the contrary, if a Participant
is determined under rules adopted by the Committee to be a &ldquo;specified employee&rdquo; within the meaning of Code Section
409A(a)(2)(B)(i) and as defined in the Corporation&rsquo;s Universal 409A Definition Document, payment under any Award hereunder
shall be delayed to the extent necessary to avoid a violation of Code Section 409A.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">(m)&nbsp;<I>Plan
Effective Date and Stockholder Approval; Expiration Date.&nbsp;</I>The Plan has been initially adopted by the Board on March 2,
2017, subject to approval by the stockholders of the Corporation, in accordance with applicable law. The Plan will become effective
on the date of such approval. Unless an extension is approved by the stockholders of the Corporation, the Plan shall have a term
that expires on May 9, 2027, after which no further Awards may be made, provided, however, that&nbsp;the&nbsp;provisions of the
Plan shall continue to apply to Awards made prior to such date. The Plan as amended was adopted by the Board on March 11, 2020,
and became effective upon approval by the Company&rsquo;s stockholders on May 14, 2020 by a vote sufficient to meet the requirements
of Section 423(b)(2) of the Code.</FONT></P>

<P STYLE="font: 12pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ss173456-ex9902.htm
<DESCRIPTION>CVS HEALTH CORPORATION 2007 EMPLOYEE STOCK PURCHASE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #454545"><B>CVS Health Corporation
2007 Employee Stock Purchase Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #454545">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&nbsp;<I>Purpose.</I></B>&nbsp;The
purpose of this 2007 Employee Stock Purchase Plan (the &ldquo;Plan&rdquo;) is to provide employees of CVS Health Corporation (the
&ldquo;Company&rdquo;) and its Designated Subsidiaries with an opportunity to purchase Stock of the Company through accumulated
payroll deductions, enabling such persons to acquire or increase a proprietary interest in the Company in order to strengthen the
mutuality of interests between such persons and the Company&rsquo;s stockholders, and to provide a benefit that will assist the
Company in competing to attract and retain employees of high quality. It is the intention of the Company that the Plan qualify
as an &ldquo;employee stock purchase plan&rdquo; under Section 423 of the Code. Accordingly, the provisions of the Plan shall be
construed in a manner consistent with the requirements of that Section of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.&nbsp;<I>Definitions.</I></B>&nbsp;For
purposes of the Plan, the following terms shall be defined as set forth below, in addition to such terms as defined in Section
1 hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) &ldquo;Account&rdquo; means the account
maintained on behalf of the participant by the Custodian for the purpose of, among other things, holding any Stock purchased by
a participant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) &ldquo;Administrator&rdquo; means the
person or persons designated to administer the Plan under Section 13(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) &ldquo;Board&rdquo; means the Company&rsquo;s
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) &ldquo;Code&rdquo; means the Internal
Revenue Code of 1986, as amended from time to time, including regulations thereunder and successor provisions and regulations thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) &ldquo;Committee&rdquo; means a committee
of two or more directors designated by the Board to administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f) &ldquo;Compensation&rdquo; base salary,
overtime, shift premiums, and commissions (all as determined before any applicable deductions from pay are made) but does not include
short or long term disability pay, incentive payments or severance pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g) &ldquo;Custodian&rdquo; means a custodian
or any successor thereto as appointed by the Board from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h) &ldquo;Designated Subsidiaries&rdquo;
means the Subsidiaries which have been designated by the Board from time to time in its sole discretion as eligible to have their
Employees participate in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) &ldquo;Employee&rdquo; means any individual
who, as of the first day of the Offering Period, has achieved 90 days of service with the Company or a Designated Subsidiary and
has been actively employed during the two month period ending with the first day of the Offering Period. To determine whether an
employee has achieved 90 days of service, the following shall apply: (i) if an individual is terminated or takes an unauthorized
leave of absence and is subsequently reemployed with the Company or a Designated Subsidiary within one year of the date of such
termination or unauthorized leave, such individual shall be credited with all service time accrued through the last</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">day the individual
was employed prior to such termination or unauthorized leave of absence; and (ii) service with an incorporated or unincorporated
entity that is controlled, directly or indirectly, by the Company shall be treated as service with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j) &ldquo;Enrollment Date&rdquo; means
the first day of the next Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k) &ldquo;Exercise Date&rdquo; means the
last day of each Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(l) &ldquo;Fair Market Value&rdquo; means
the fair market value of a share of Stock as determined by the Committee or under procedures established by the Committee. Unless
otherwise determined by the Committee, the Fair Market Value of Stock as of any given date shall be the closing price of a share
of Stock reported on a consolidated basis for securities listed on the New York Stock Exchange for trades on the date as of which
such value is being determined or, if that day is not a Trading Day, then on the latest previous Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(m) &ldquo;Offering Period&rdquo; means
the approximately six month period commencing on the first Trading Day on or after January 1 and July 1, respectively, and terminating
on the last Trading Day in the following June and December, respectively. The beginning and ending dates and duration of Offering
Periods may be changed pursuant to Section 4 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n) &ldquo;Purchase Price&rdquo; means
an amount equal to 90% of the Fair Market Value of a share of Stock on the Enrollment Date or 90% of the Fair Market Value of a
share of Stock on the Exercise Date, whichever is lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(o) &ldquo;Reserves&rdquo; means the number
of shares of Stock covered by all options under the Plan which have not yet been exercised and the number of shares of Stock which
have been authorized for issuance under the Plan but which have not yet become subject to options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(p) &ldquo;Stock&rdquo; means the Company&rsquo;s
Common Stock, and such other securities as may be substituted (or resubstituted) for Stock pursuant to Section 18 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(q) &ldquo;Subsidiary&rdquo; means any
corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations
(other than the last corporation in the unbroken chain) owns stock possessing 50% or more of the total combined voting power of
all classes of stock in one of the other corporations in the chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(r) &ldquo;Trading Day&rdquo; means a day
on which the New York Stock Exchange is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.&nbsp;<I>Eligibility.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) All Employees (as determined in accordance
with Section 2(i) hereof) of the Company or a Designated Subsidiary on a given Enrollment Date shall be eligible to participate
in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Any provisions of the Plan to the contrary
notwithstanding, no Employee shall be granted an option under the Plan (i) to the extent that, immediately after the grant, such
Employee (or any other person whose Stock would be attributed to such Employee pursuant to Section 424(d) of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Code) would own
capital stock and/or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or
value of all classes of the capital stock of the Company or of any Subsidiary, or (ii) to the extent that his or her rights to
purchase stock under all employee stock purchase plans of the Company and its Subsidiaries accrue at a rate which exceeds $25,000
worth of stock (determined at the fair market value of the shares at the time such option is granted) for each calendar year in
which such option is outstanding at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) All participants in the Plan shall
have equal rights and privileges (subject to the terms of the Plan) with respect to options outstanding during any given Offering
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&nbsp;<I>Offering Periods.</I></B>&nbsp;The
Plan shall be implemented by consecutive Offering Periods with a new Offering Period commencing on the first Trading Day on or
after January 1 and July 1 of each year following the initial Offering Period, or on such other date as the Committee shall determine,
and continuing thereafter until terminated in accordance with Section 19 hereof. The Committee shall have the power to change the
beginning date, ending date, and duration of Offering Periods with respect to future offerings without stockholder approval if
such change is announced at least five days prior to the scheduled beginning of the first Offering Period to be affected thereafter,
provided that Offering Periods will in all cases comply with applicable limitations under Section 423(b)(7) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5.&nbsp;<I>Participation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Any person who will be an eligible
Employee on a given Enrollment Date may become a participant in the Plan by completing a subscription agreement authorizing payroll
deductions and filing it with the Administrator prior to such deadline as the Administrator may prescribe for such Enrollment Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Payroll deductions for a participant
shall commence on the first payroll following the Enrollment Date and shall end on the last payroll in the Offering Period to which
such authorization is applicable, unless sooner terminated by the participant as provided in Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6.&nbsp;<I>Payroll Deductions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) At the time a participant files his
or her subscription agreement, he or she shall elect to have payroll deductions made on each pay day during the Offering Period
in an amount from 1% to 15% of the Compensation which he or she receives for each pay period during the Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) All payroll deductions made for a participant
shall be credited to his or her Account under the Plan. Payroll deductions shall be withheld in whole percentages only, unless
otherwise determined by the Committee. A participant may not make any additional payments into such Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) A participant may discontinue his or
her participation in the Plan as provided in Section 10 hereof, or may decrease the rate of his or her payroll deductions during
the Offering Period, by completing and filing with the Administrator a new subscription agreement authorizing a change in payroll
deduction rate. Unless otherwise authorized by the Committee, a participant may not change or discontinue his or her payroll deduction
rate more than twice during an Offering Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The change in rate shall be effective with the first payroll period following the
first of the month after the Administrator&rsquo;s receipt of the new subscription agreement provided the change in rate election
is received by the last business day prior to the fifteenth (15th) of the preceding month, unless the Company elects to process
a given change in participation more quickly. A participant&rsquo;s subscription agreement shall remain in effect for successive
Offering Periods unless terminated as provided in Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) The foregoing notwithstanding, to the
extent necessary to comply with Section 423(b)(8) of the Code and Section 3(b) hereof, a participant&rsquo;s payroll deductions
may be terminated at such time during any Offering Period which is scheduled to end during the current calendar year (the &ldquo;Current
Offering Period&rdquo;) that the aggregate of all payroll deductions accumulated with respect to the Current Offering Period and
any other Offering Period ending in the same calendar year do not exceed $21,250 (or such other limit as may apply under Code Section
423(b)(8)). Payroll deductions shall recommence at the rate provided in such participant&rsquo;s subscription agreement (as previously
on file or as changed prior to the recommencement date in accordance with Section 6(c)) at the beginning of the next Offering Period
which is scheduled to end in the following calendar year, unless terminated by the participant as provided in Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e) The Company or any Designated Subsidiary
is authorized to withhold from any payment to be made to a participant, including any payroll and other payments not related to
the Plan, amounts of withholding and other taxes due in connection with any transaction under the Plan, including any disposition
of shares acquired under the Plan, and a participant&rsquo;s enrollment in the Plan will be deemed to constitute his or her consent
to such withholding. At the time of a participant&rsquo;s exercise of an option or disposition of shares acquired under the Plan,
the Company may require the participant to make other arrangements to meet tax withholding obligations as a condition to exercise
of rights or distribution of shares or cash from the participant&rsquo;s Account. In addition, a Participant may be required to
advise the Company of sales and other dispositions of Stock acquired under the Plan in order to permit the Company to comply with
tax laws and to claim any tax deductions to which the Company may be entitled with respect to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.&nbsp;<I>Grant of Option.</I></B>&nbsp;On
the Enrollment Date of each Offering Period, each eligible Employee participating in such Offering Period shall be granted an option
to purchase on the Exercise Date of such Offering Period, at the applicable Purchase Price, up to a number of shares of Stock determined
by dividing such Employee&rsquo;s payroll deductions accumulated prior to such Exercise Date and retained in the Participant&rsquo;s
Account as of the Exercise Date by the applicable Purchase Price; provided that such purchase shall be subject to the limitations
set forth in Sections 3(b) and 12 hereof. Exercise of the option shall occur as provided in Section 8 hereof, unless the participant
has withdrawn pursuant to Section 10 hereof. To the extent not exercised, the option shall expire on the last day of the Offering
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8.&nbsp;<I>Exercise of Option.</I></B>&nbsp;Participant&rsquo;s
option for the purchase of shares shall be exercised automatically on the Exercise Date, and the maximum number of shares subject
to option shall be purchased for such participant at the applicable Purchase Price with the accumulated payroll deductions in his
or her account. Shares purchased shall include fractional shares calculated to at least three decimal places, unless otherwise
determined by the Committee. If fractional shares are not to be purchased for a participant&rsquo;s Account, any payroll deductions
accumulated in a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">participant&rsquo;s account not sufficient to purchase a full share shall be retained in the participant&rsquo;s
account for the subsequent Offering Period, subject to earlier withdrawal by the participant as provided in Section 10 hereof.
During a participant&rsquo;s lifetime, a participant&rsquo;s option to purchase shares hereunder is exercisable only by him or
her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9.&nbsp;<I>Delivery of Shares; Participant
Accounts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) At or as promptly as practicable after
the Exercise Date for an Offering Period, the Company will deliver the shares of Stock purchased to the Custodian for deposit into
the participant&rsquo;s Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Cash dividends on any Stock credited
to a participant&rsquo;s Account under the Plan shall be reinvested in additional shares of stock or credited in the form of cash,
dependent on the participant&rsquo;s election in accordance with established procedures. If no election is made by a participant,
dividends will be applied as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">(1) For Accounts established prior
to November 1, 2018,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify">(a) if the Account holds ESPP
shares only, cash dividends on any Stock credited to a participant&rsquo;s Account will be automatically reinvested in additional
shares of Stock; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify">(b) if the Account holds ESPP
shares and non-ESPP shares, cash dividends on any Stock credited to a participant&rsquo;s Account will be credited in the form
of cash; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">(2) For all Accounts established
after October 31, 2018, cash dividends on any Stock, whether ESPP shares or non-ESPP shares, credited to a participant&rsquo;s
Account will be credited in the form of cash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All cash dividends paid on Stock credited
to participants&rsquo; Accounts will be paid over by the Company to the Custodian at the dividend payment date. The Custodian will
aggregate all purchases of Stock in connection with the Plan for a given dividend payment date. Purchases of Stock for purposes
of dividend reinvestment will be made as promptly as practicable (but not more than 30 days) after a dividend payment date. The
Custodian will make such purchases, as directed by the Committee, either (i) in transactions on any securities exchange upon which
Stock is traded, otherwise in the over-the-counter market, or in negotiated transactions, or (ii) directly from the Company at
100% of the Fair Market Value of a share of Stock on the dividend payment date. Any shares of Stock distributed as a dividend or
distribution in respect of shares of Stock or in connection with a split of the Stock credited to a participant&rsquo;s Account
will be credited to such Account. In the event of any other non-cash dividend or distribution in respect of Stock credited to a
participant&rsquo;s Account, the Custodian will, if reasonably practicable and at the direction of the Committee, sell any property
received in such dividend or distribution as promptly as practicable and use the proceeds to either purchase additional shares
of Common Stock in the same manner as cash paid over to the Custodian for purposes of dividend reinvestment or apply cash dividends,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Each participant will be entitled to
vote the number of shares of Stock credited to his or her Account (including any fractional shares credited to such Account) on
any matter as to which the approval of the Company&rsquo;s stockholders is sought. If a participant does not vote or grant a valid
proxy with respect to shares credited to his or her Account, such shares will be voted by the Custodian in accordance with any
stock exchange or other rules governing the Custodian in the voting of shares held for customer accounts. Similar procedures will
apply in the case of any consent solicitation of Company stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10.&nbsp;<I>Withdrawal of Payroll Deductions
or Shares; Termination of Employment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) If a participant decreases his or her
payroll deduction rate to zero during an Offering Period, payroll deductions shall not resume at the beginning of the succeeding
Offering Period unless the participant delivers to the Administrator a new subscription agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Upon a participant&rsquo;s ceasing
to be an Employee for any reason (including upon the participant&rsquo;s death), he or she shall be deemed to have elected to withdraw
from the Plan and the payroll deductions credited to such participant&rsquo;s Account during the Offering Period but not yet used
to exercise the option shall be returned to such participant or, in the case of his or her death, to the person or persons entitled
thereto under Section 14 hereof, and such participant&rsquo;s option shall be automatically terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) During the twenty-four (24) month period
from the first day of each Offering Period a participant (whether or not still an Employee) may not withdraw or transfer shares
of Stock acquired during such Offering Period except on account of the participant&rsquo;s death or such other reason as the Committee
may promulgate in its discretion from time to time. After the end of such twenty-four (24) month period, the participant may elect
to withdraw, transfer or receive a certificate for such shares. If a participant elects to withdraw shares in certificated form,
one or more certificates for whole shares shall be issued in the name of, and delivered to, the participant, with such participant
receiving cash in lieu of fractional shares based on the Fair Market Value of a share of Stock on the date of withdrawal. If shares
of Stock are transferred from a participant&rsquo;s Account to a broker-dealer or financial institution that maintains an account
for the participant, only whole shares shall be transferred and cash in lieu of any fractional share shall be paid to such participant
based on the Fair Market Value of a share of Stock on the date of transfer. A Participant seeking to withdraw, sell or transfer
shares of Stock must give instructions to the Custodian in such manner and form as may be prescribed by the Committee and the Custodian,
which instructions will be acted upon as promptly as practicable. Transfers and withdrawals will be subject to any fees imposed
in accordance with Section 10(d) hereof. A participant may sell shares of Stock at any time following purchase and shall be responsible
for any and all tax consequences related to such sale, including as a result of the timing of such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Costs and expenses incurred in the
administration of the Plan and maintenance of Accounts will be paid by the Company, including annual fees of the Custodian and
any brokerage fees and commissions for the purchase of Stock upon reinvestment of dividends and distributions. The foregoing notwithstanding,
the Custodian may impose or pass through a reasonable fee for the withdrawal of Stock in the form of stock certificates (as permitted
under Section 10(c)), and reasonable fees for other services unrelated to the purchase of Stock under the Plan, to the extent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">approved
in writing by the Company and communicated to participants. In no circumstance shall the Company pay any brokerage fees and commissions
for the sale of Stock acquired under the Plan by a participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11.&nbsp;<I>Interest.</I></B>&nbsp;No
interest shall accrue on the payroll deductions of a participant in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12.&nbsp;<I>Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The maximum number of shares of Stock
which shall be made available for sale under the Plan shall be&nbsp;sixty (60) million shares, subject to adjustment as provided
in Section 18 hereof. If, on a given Exercise Date, the number of shares with respect to which options are to be exercised exceeds
the number of shares then available under the Plan, the Company shall make a pro rata allocation of the shares remaining available
for purchase in as uniform a manner as shall be practicable and as it shall determine to be equitable. Any shares of Stock delivered
by the Company under the Plan may consist, in whole or in part, of authorized and unissued shares or shares acquired by the Company
in the open market. Shares acquired in the open market through dividend reinvestment will not count against the Reserves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The participant shall have no interest
or voting right in shares purchasable upon exercise of his or her option until such option has been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>13.&nbsp;<I>Administration.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The Plan shall be administered by the
Committee except to the extent the Board elects to administer the Plan, in which case references herein to the &ldquo;Committee&rdquo;
shall be deemed to include references to the &ldquo;Board&rdquo;. The Committee shall have full and final authority to construe,
interpret and apply the terms of the Plan, to determine eligibility and to adjudicate all disputed claims filed under the Plan.
The Committee may, in its discretion, delegate authority to the Administrator. Every finding, decision and determination made by
the Committee or Administrator shall, to the full extent permitted by law, be final and binding upon all parties (except for any
reserved right of the Committee to review a finding, decision or determination of the Administrator). The Committee, Administrator,
and each member thereof shall be entitled to, in good faith, rely or act upon any report or other information furnished to him
or her by any executive officer, other officer or employee of the Company or any Designated Subsidiary, the Company&rsquo;s independent
auditors, consultants or any other agents assisting in the administration of the Plan. Members of the Committee or Administrator
and any officer or employee of the Company or any Designated Subsidiary acting at the direction or on behalf of the Committee shall
not be personally liable for any action or determination taken or made in good faith with respect to the Plan, and shall, to the
extent permitted by law, be fully indemnified and protected by the Company with respect to any such action or determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) The Custodian will act as custodian
under the Plan, and will perform such duties as are set forth in the Plan and in any agreement between the Company and the Custodian.
The Custodian will establish and maintain, as agent for each Participant, an Account and any subaccounts as may be necessary or
desirable for the administration of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14.&nbsp;<I>Designation of Beneficiary.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) A participant may file a written designation
of a beneficiary who is to receive any shares and cash, if any, from the participant&rsquo;s Account under the Plan in the event
of (i) such participant&rsquo;s death subsequent to an Exercise Date on which the option is exercised but prior to a distribution
to such participant of shares or cash then held in the participant&rsquo;s Account or (ii) such participant&rsquo;s death prior
to exercise of the option, in accordance with procedures established by the Committee or Administrator. If a participant is married
and the designated beneficiary is not the spouse, spousal consent shall be required for such designation to be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Such designation of beneficiary may
be changed by the participant at any time by written notice. In the event of the death of a participant without a valid designated
beneficiary who is living at the time of such participant&rsquo;s death, any shares or cash otherwise deliverable under Section
14(a) shall be deliverable to the participant&rsquo;s surviving spouse or, if there is no surviving spouse, to such participant&rsquo;s
estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15.&nbsp;<I>Transferability.&nbsp;</I></B>Neither
payroll deductions credited to a participant&rsquo;s account nor any rights with regard to the exercise of an option or to receive
shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of
descent and distribution or as provided in Section 14 hereof) by the participant. Any such attempt at assignment, transfer, pledge
or other disposition shall be without effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16.&nbsp;<I>Use of Funds.&nbsp;</I></B>All
payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the
Company shall not be obligated to segregate such payroll deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>17.&nbsp;<I>Reports.&nbsp;</I></B>An
individual Account shall be maintained by the Custodian for each participant in the Plan. Statements of Account shall be given
to each participant at least annually, which statements shall set forth the amounts of payroll deductions, the Purchase Price,
the number of shares purchased, any remaining cash balance, and other information deemed relevant by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>18.&nbsp;<I>Adjustments Upon Changes
in Capitalization, Dissolution, Liquidation, Merger or Asset Sale.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;<I>Changes in Capitalization</I>.
The Committee shall proportionately adjust the Reserves and the price per share and the number of shares of Stock covered by each
option under the Plan which has not yet been exercised for any increase or decrease in the number of issued shares of Stock resulting
from a stock split, reverse stock split, stock dividend, combination or reclassification of the Stock, or other extraordinary corporate
event which affects the Stock in order to prevent dilution or enlargement of the rights of participants. The determination of the
Committee with respect to any such adjustment shall be final, binding and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;<I>Dissolution or Liquidation</I>.
In the event of the proposed dissolution or liquidation of the Company, the Offering Period shall terminate immediately prior to
the consummation of such proposed action, unless otherwise provided by the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;<I>Asset Sale or Merger</I>. In
the event of a proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into
another corporation, the Committee shall shorten the Offering Period then in progress by setting a new Exercise Date (the &ldquo;New
Exercise Date&rdquo;). The New Exercise Date shall be before the date of the Company&rsquo;s proposed asset sale or merger. The
Committee shall notify each participant in writing, at least ten business days prior to the New Exercise Date, that the Exercise
Date for the participant&rsquo;s option has been changed to the New Exercise Date and that the participant&rsquo;s option shall
be exercised automatically on the New Exercise Date, unless prior to such date the participant has withdrawn from the Offering
Period as provided in Section 10 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>19.&nbsp;<I>Amendment or Termination.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The Board (and the Committee or the
Administrator except with respect to the number of shares of Stock available under the Plan under Section 12) may at any time and
for any reason terminate or amend the Plan. Except as provided in Section 18 hereof, no such termination can affect options previously
granted, provided that an Offering Period may be terminated by the Board of Directors by shortening the Offering Period and accelerating
the Exercise Date to a date not prior to the date of such Board action if the Board determines that termination of the Plan is
in the best interests of the Company and its stockholders. Except as provided in Section 18 and this Section 19, no amendment may
make any change in any option theretofore granted which materially adversely affects the rights of any participant, and any amendment
will be subject to the approval of the Company&rsquo;s stockholders not later than one year after Board approval of such amendment
if such stockholder approval is required by any federal or state law or regulation or the rules of any stock exchange or automated
quotation system on which the Stock may then be listed or quoted, or if such stockholder approval is necessary in order for the
Plan to continue to meet the requirements of Section 423 of the Code, and the Board may otherwise, in its discretion, determine
to submit any amendment to stockholders for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Without stockholder consent and without
regard to whether any participant rights may be considered to have been &ldquo;adversely affected,&rdquo; the Committee shall be
entitled to change the Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering
Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding
in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company&rsquo;s processing
of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Stock for each participant properly correspond with amounts withheld
from the participant&rsquo;s Compensation, and establish such other limitations or procedures as the Committee determines in its
sole discretion are advisable and consistent with the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>20.&nbsp;<I>Notices.&nbsp;</I></B>All
notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been
duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for
the receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>21.&nbsp;<I>Conditions Upon Issuance
of Shares.&nbsp;</I></B>The Company shall not be obligated to issue shares with respect to an option unless the exercise of such
option and the issuance and delivery of such shares pursuant thereto shall comply with all applicable provisions of law, domestic
or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended,
the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon
which the shares may then be listed or quoted, and shall be further subject to the approval of counsel for the Company with respect
to such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>22.&nbsp;<I>Plan Effective Date and
Stockholder Approval.&nbsp;</I></B>The Plan was adopted by the Board on March 7, 2007, and became effective upon approval by the
Company&rsquo;s stockholders on May 9, 2007 by a vote sufficient to meet the requirements of Section 423(b)(2) of the Code. The
Plan as amended was adopted by the Board on March 6, 2013, and became effective upon approval by the Company&rsquo;s stockholders
on May 9, 2013 by a vote sufficient to meet the requirements of Section 423(b)(2) of the Code. Additional amendments not requiring
approval by the Company&rsquo;s stockholders were adopted by the Board on November 4, 2015 and became effective on January 1, 2016
and adopted by the Company&rsquo;s Executive Vice President, Chief Human Resources Officer in accordance with Section 13 of the
Plan pursuant to delegated authority from the Committee effective October 1, 2018 and July 1, 2019. The Plan as further amended
was adopted by the Board on March 11, 2020, and became effective upon approval by the Company&rsquo;s stockholders on May 14, 2020
by a vote sufficient to meet the requirements of Section 423(b)(2) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! "6     $  0)8
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MM+P:7"B.Y)#QRQZPD6./<:S(,VBV[8_>)2F^[1/95Y7;V@ XC_M]^LE^L)Y
M?PQ8_P P@ ?;[]9+]83R _ABQ_F$ #[??K)?K">0'\,6/\P@ ?;[]9+]83R
M_ABQ_F$ &1^C?-$]:'2=SA2)G*&W[KL$1Q+CV'[RUAK[+;9<NZ[XE43<EL5A
MQ/9:&UTK5%:1[\Q^#7X.RJ4U2 .MOI@>;OXQ<I,AQ[3O.7#;3P_VI>WH-JLV
MT(5]EWKCGE-ZDU:8HU=[M=VDW_3:IDMWL9K=WKG9V6DU5)N[->ZE0 ["H\B/
M,CL2XC[,J+*9:D1I,=U#\>1'?0EUE]AYI2FWF7FU44E2:U2I-:5I7L !_L
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MG&M]C<G-1XAG&'WNZ6=VT9+C-\RVW0;M9KDVS9F75PY\1U3;E$K36J:_!6@
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M-8YD%FOKF-Y/+LMRQK($6BXQK@NR9#;DV9A4^QW5,?P);-%HJ['<6GO4[>T
M%:'@?S&UGS]XDZ0Y:ZG=2WB^W\-AWF=85RJ3)^$9E!<=L^>:_O#_ ($7QKM@
M^86^;;77J-(:E>C4D,]YAUI:@!ER     "7?UUNL3U.N.'5CYDZ3T;S/W)K3
M5.!9IA=OP[!L;N=I8LF/PKAJ37U[FQ[>U(M$AY#<B[720^KO+5^,=5_^@ &I
M7[??K)?K">0'\,6/\P@ I4>7#Y';QY7=)S1N[.1>R\DVWM;(\TW=;[YG.6/Q
MY%[N4+'MMY;9+)'DNQ8\5E3=MM,%IAOL13L;;IV]O[H -Z0
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M^J; P?"K.TW>-D[4R:)&1(IBNNL23(CR+U<J^,U21)=<C6NV(>0]/E16*^*
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M?L<D/(EVBZM,1Y,S&\LQZXL0LBPW++:S+:5)M=UBQ)["74*6U1+B%* &1@
M     )W_ )HWJE=0CASU*[%J3C#RNVII?6\GC)JW+W\/PVX6V+:'<FO.6;-A
M72\J;EVR8[Z9-B6B,VNO?[*I93\  .<7[??K)?K">0'\,6/\P@ ?;[]9+]83
MR _ABQ_F$ #[??K)?K">0'\,6/\ ,( 'V^_62_6$\@/X8L?YA  ^WWZR7ZPG
MD!_#%C_,( 'V^_62_6$\@/X8L?YA ![/QPZ['5YROD/H;%LCY\;XN^/9+N?5
MU@OMIEW>RJBW.S7G.+';KI;Y*4V-"E1YL&2MM=*5I6J55^$ %A,
M$87[??K)?K">0'\,6/\ ,( 'V^_62_6$\@/X8L?YA  ^WWZR7ZPGD!_#%C_,
M( 'V^_62_6$\@/X8L?YA  ^WWZR7ZPGD!_#%C_,( 'V^_62_6$\@/X8L?YA
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M]W_MU,@R_97VU^<M[5^J_0H$+P_7GLE;?'[W>[?0V^SL[*]H [/0
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M[_?:W/<I>8D7Z_>S/)_=6'V'TYZ,Q&97ZKQG'X4)KNH3V,QT4KVUI6M0!N>
M          !HPZL_7YX7]*2WR\+RJ?(WARBF6?UECG'#7=UA-WBWTDL-O6NY
M;9RU;-QMFJL?N"'FW&O2(\R\2F%T>B6Z2S1;B !/YYI^:$ZLG+FYW6%BFZU<
M2=;2U+;M^"<8DRL$O<:/2B6V'YVWW9$[;DB[>&GM><A7>VPUN*JI$1JG=2D
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M=])Q',,YQ>[)8V!ONT1)[+CN/^J';;3%F7K8ZTU?'T3TW!MQ5IMRT #N%
M      !Q!>=Y^BSP>^/_ &)\G4< $X0 '9YY)CZ??*[ZG\GY:-6@ I>
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M*'QFP'PGJR8T2SZ2;>QO*Z0I/P-2(-UVNO(KDRMNGA*1.I5%5T_&+ &C,
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MR0P+7\"'6X7C-)VL[_<L9QV"EM3JY>57FPQ[K Q..A*:]Y5R7%HFOP5[*_
M#7J #(_B-RJW%PEY&ZHY0Z&R%S'-F:DRB+D-G=4I^MKOEO4AR%D6'Y+%CO1W
M+CB>9X_*DVRZ1J+15^%*<2E2%]U:0!;+X7<J, YN\5-$<K]8J4C#MX:]L^91
M;<Z\F1*QR\N>+;<NPVXOH0VT]=L)R^WS[1,6BGAJE0G*HK5/96H R>
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M@         '$%YWGZ+/![X_]B?)U' !.$ !V>>28^GWRN^I_)^6C5H *7@
M     ((VU_YTME?R_P Q_2*X@ ^  !>XU-_-7K3XO\-_1RV@ ]
M!*$\WC]\EFOQ :)_(5S !S!  J]>4-^YMPOZP&]ORY:P =/P
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M>NE]?;(EVMK_ ";'?<DQR#,R;':U\1ZE7,<R-4J"NM%K35<>O8I5.RM0!E
M        ",+U]_ODNH3]8"\?D.P@ U @   Z<_*9\P:\:>JUB6JKY=%0L"Y@
MX+D6C+JT^XE%N8SZ&A.=ZJNKJ>\EQ=RDY#C;V/Q.[WJ=[(ET4GLKWT "L*
M   "7'YQ3F%[\^H_B/&:PW7TS#>&^J[=8KE$9E>DPT;>W&S:=@YU*84U7T9+
MC6%(Q.WOHIWG&9=O?0M5%4JVV .2,   &S[HI_>W].7ZX&COTXM0 +70
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MOOM>>_Q@:^^1#5X -(( *W7E/_N2N.7Q@<B/EOS< '1\
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M>F]2SZ__ #(_O%;& !@  "UST4ONC^G+]4#1_P"A-K !L_
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M0I\NWY:'6[^N< YW]1G7K.;9)FT&-ENBN+V;6U#^'8[B%QCQ)N,[)W%CTO\
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M\/LUOO.%YK6V-*I13JL*N4RT+?1WJJ4W>*+2GNMNJH ._L
M     '$%YWGZ+/![X_\ 8GR=1P 3A  =GGDF/I]\KOJ?R?EHU: "EX
M ""-M?\ G2V5_+_,?TBN( /@  7N-3?S5ZT^+_#?T<MH /0          2A/
M-X_?)9K\0&B?R%<P <P0 *O7E#?N;<+^L!O;\N6L '3\
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M+;BV7"=C(N$AC4&SI+\A;4:WP[9>[S(L]T?<<:CLVJ\NRGZJ]":[H K1@
MCB^9"^^UY[_&!K[Y$-7@ T@@ K=>4_\ N2N.7Q@<B/EOS< '1\
M           "!#DF/W3$\AOV+7R,J'>\:O5TQ^\1%T51<6Z6:<_;KA&51:4+
MHIB7&6FM*TI7MI\-*  _3P#,KGKK.\)V#94LKO."Y=C>96E$A-%QUW/&+S"O
M<!+Z%)6E;*I4%%%4K2M*I[?@ !=QT+NK ^1^D]3[^UA=6;WKW<FO<2V3B%Q9
M<0XIVQY?98=[A,2THK6L:Y043/ EL+HEV-):<:<2E:%)H /6@ ?YK9:<4RMQ
MIMQ<=RKS"UH2I3#JFG6*NLJ52M6W*L/K152>RO<6JG[E:@ _T
M              !/S\\M"O-+KTS;BY*\7'E6_E["APDQ4T] O*9/&A^Y2GIJ
M6J*7ZV@KBH::4NM$^A.*2FG>76H X$P ==WDU>0^N]3]2#:6H<XGVFR7ODAQ
M]NN*ZRN=QJVT_=,ZP?*[#FRL)@2G%)2T]D.(PKK-2BM?WP]:6FD]KBFTJ %0
MH                       $0;JQ?>F]2SZ_P#S(_O%;& !@  "UST4ONC^
MG+]4#1_Z$VL &S\             $ <   %WCB;]%CC1]7_37R=8X #(
M              '$%YWGZ+/![X_]B?)U' !.$ !V^>2&^E/S@^K_ *]^45\
M%'P     $27K :@L.ANJ-SUU9BK$>'B^/<H-KS<;ML1/<B6>P97DTS,;/8HR
M/"9[D>Q6Z_MPT4[*]B6*4[RO\JH UP@ KE>5/S:1E_1*XRVV5</6#^ 9AO\
MPGM762N3#CHWAG650+?)>DK71WT2WY4TECP^QIJ+X35*4\.M  =%P
M  (@W5B^]-ZEGU_^9']XK8P ,   6N>BE]T?TY?J@:/_ $)M8 -GX
M        )X?GB_YU.G;\7_([](]0  X0P =_GD8__=$_J3?^K@ '?X
M   #0#YH[[BCG-_5F_OA\?0 2!0     =5?E2.J'3A=S;3Q7VCD*H''KFE<K
M)A;3MPE+1:,%Y!,JK!U9E7=4A]$6+F[TFN+7!2*-)6]/MTF2ZF/;Z]@ JF@
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MWF&&WZU9/B^06UU2DM7"R9!9)4ZTW6"XI%:)=8><;K6E>ROP  ^F
M       !Q!>=Y^BSP>^/_8GR=1P 3A  =GGDF/I]\KOJ?R?EHU: "EX
M  ""-M?^=+97\O\ ,?TBN( /@  7N-3?S5ZT^+_#?T<MH /0          2A
M/-X_?)9K\0&B?R%<P <P0 *O7E#?N;<+^L!O;\N6L '3\
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MA[STS@&QI<&'5RK%ER#(<=@RLJQOM=_#\;%\G],MSOPJIXL578I5.Q50!D\
M          #A"\\7_-;T[/Y?\C_T=T\ ">( #M\\D-]*?G!]7_7ORBO@ H^
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MK+]8I8==2[.<UYG#ZMJ8)<Y'8JKB8J;AE%ZM$6BJ4[K-EHFGP)IV #JD
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M?:\]_C U]\B&KP :00 5NO*?_<E<<OC Y$?+?FX .CX
M    $>?S('!^[\).JQR%C1K3*B:PY'WZ?R?U/<E,H1;Y5KVS>+E>,YL4&L="
M8D5.&[1I>K<U$I6CK%N:AN*31#[55 #0^ #OC\H?UA[5CZ4]*?D)D[<"-=;Q
M?,IX<9->I7A0D7:\.S<@SO0KTQ]Y,>&Y>;HJ3?L:0I*?2;A)N4/Q5/OVV,L
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M/D151VV7DVN_;UV(QC\I]QMQRDOUKCUMBS&G*]U5(\AM%:4J@ '0<
M  "(-U8OO3>I9]?_ )D?WBMC  P  !:YZ*7W1_3E^J!H_P#0FU@ V?@
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MT:#>,DW'*9>0A2:ONVE%7$UHTS4 ';.
M  "$-RP^E-R5^/\ W)\HN1@ \  !<XZ>OT!.#OU/^-'R+X4 #,
M    &'_4*^@)SB^I_P E_D7S4 $,< &7_3V^GUP>^M_QI^6?"@ 7.0
M         0AN6'TIN2OQ_P"Y/E%R, '@  +O/$_Z+/&KX@--_)UC@ /?P
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M06K*L3R2TR*J2S<K%D-CESK3=8+BD*I1UAU:*J36G;VTJ #ZX
M'$%YWGZ+/![X_P#8GR=1P 3A  9 \=^5W)7B1D][S7C%O/9VALMR2PUQ>_Y'
MJW+KOA]XO&.*N$*[*LEPG6>1&?E6VMSMS#_A*K5'BLH5V=M*  R]^VLZM_ZQ
MKF!_MQSC\Z@ ?;6=6_\ 6-<P/]N.<?G4 #[:SJW_ *QKF!_MQSC\Z@ ?;6=6
M_P#6-<P/]N.<?G4 &LN=-EW*;+N-PDO3)\^5(FS9<AQ3LB5+E.K?DR7W5UJI
MQY]YQ2E*K\-55K4 '\H +W&IOYJ]:?%_AOZ.6T 'H          )0GF\?ODL
MU^(#1/Y"N8 .8( &S+BUUC>I9PIU/$T;Q>Y599J35,"^7K)(F'6?$]97B$S>
M\A>;D7FX)FY3A%^NRG)SS*5*3615M/9^"E( ,C/VD+K:_P#'OL#_ &?:0_W7
M@ ?M(76U_P"/?8'^S[2'^Z\ #]I"ZVO_ ![[ _V?:0_W7@ SXZ6/7HZN&^>H
M_P (M+[<YHYMFFL-H<EM3X3GF)S<(U#"AY%BV099;[?>+1)F6C7ENND9F=#>
M4A2X[[+J:5[4KI7X0 50@           :#_,Q<KU\4.C]R6EVNZ)M>9\@F;)
MQ;PI57JL.3)&X538^?1(ZT?C/2DZ8LN3O-]WL513-*]M*4K4 $?< '2;Y4;B
M^YR(ZOVJ<PN%M<G8EQ<P//\ D)?UN-II!3=K;;X^O< :<D.)\.EPC9[L"WW*
M.RFOC.4MKBTTJVTZI( K5@ FE^=2XP^P/-/C=RJM%N]'LW(C2=PP'))3$;\7
M)V%HJ^M(>N-PEHIV4F7' MA6.(PASLJMJT*JBJJ(71  XNP 5#O)M\K:[CZ;
MV?<;+Q</2<EXA[HNUMM,/ON.+B:JW;2?L7$7GENNK51Q_83.9-)0E*6T,1FZ
M4[:][L '74           #A"\\7_ #6].S^7_(_]'=/  GB  [1/)?;.UMK+
MD[S2G;)V%@^O8-TT/@,2VS,XRRPXG%N,IG8+SSL:#(OT^ S+D-,U[ZD-U4I*
M?AK3L !0T^=EQ8_XE^/_ /MEUU_XC !\GF/.[A%KRT/7_/.8G%O#;*PV\ZY<
M\FW]JFRP^ZPCQ':-OW#*XZ'G$H_ZB.\NO;2E*5K6@ .-SKR^:4TID.E]C<-^
MFKEMVS_*-FV6ZX/M+E+:XEPQW#L/PV[LNVK*<9T\Y>(4*_Y/EV0VYR1"<R%I
MB);K7%=\>UR9DEUN1! $]8 'J>CM,;"Y%[DU=H74]D<R/96X<\Q?7.$69%5H
M;F9'EMWBV:VUFR$MNT@6N,_+H]+E+IX42*VX\Y6B$*K0 7,^,FA\5XN\=-%\
M;\(JIS$]%:EP#5%BE.-I:DW*%@F,6S'$WB<E-:T5<KRY;U2Y*ZUJIR0\M5:U
MK6M0 >Y          C"]??[Y+J$_6 O'Y#L( -0( *C'#/A^GG;Y2G7O&F';
M$W3+\PXU;9R#5\=,:C\JNW-=;VV1L/6$>&XFGI$15WS/&(=O?<:[7*PY;R.Z
MM*U-K $NE:%-J4A:5(6A54+0NE4J0I-:T4E2:TI5*DUIV5I7X:5 !U"^4DY@
MTXW]5&QZ>OUT3!P/F+KW(M,S42G%(M[&Q;$VK8.K+HY1"J*7<I=RQ^;CT.E:
M+3XF15I6E.VBT "KB "6]YP[F4UOKJ/8KQGQN[*G87PRUC#QJZ1FWG'H2-Q[
M<;M6>Y_)BJI1$52F,.;Q2VOI1WU,S;<^VM??35ML <E  *HF)\/J<(?*?;DT
M]<K6FV9Y?^G]N?<VU4+;4W</>+N?#+ML&[VN[T4E":W+#;;>H>/*JFG=\.T(
MI2J^SOJ $KL &S[HI_>W].7ZX&COTXM0 +70           /B=E["Q74>N,_
MVOG5Q3:,(UCA.5;"S&[+HFJ+7BN%V*?DF0W%5%K;15,*T6UYVO:I-.Q/PUI^
MZ "%)R.W;D_)3D#N[D-FBW%99O#;&P-KW]#C]9%(MSS[*;ID\F PY5#2:0[:
MJY>CL(0A#;;+:4(2E*:)H /^N-VE,AY)\A=&<>L3[R<EWEM[7.I+&]1NKB8E
MRV%EUHQ2-.>I1*J)BP'+KX[RZ_@MM-J4JM$TK4 %V7!<+Q[6^$8=KO$8*;9B
MF!8KCV%XQ;4=E46_'L6M$.QV6"FJ4H35,2VP6FZ=E*4[$_N4 !S+^;NXOIWI
MTG;OMJUVWTK*>)VX, VVU*CMMKN'L3E$F1J7-[6COI4OU75>=6Z[2Z([JJ4L
MJ%U5W$+HH 2F0 ==_DV>5Z=.=1O8?&F\W143&^7FF;E!M$"KU&F)^UM(5N6P
ML1<>2O\  6J/KR7F3;5.VBZNR$I3V]ZM*@"H2           #4!U^/N;>H3\
M0%W_ "[80 1A@ ;?N@1]\ET]OK 6?\AWX '7'YQ;I=TV#K+#>ISJ+'%.YEJ.
M+:=7\FH=IA+<?OFJ[A<? UWLJ6U%;IWY6O<DN2[1<9"TNO.VNZPZK6W&M8 )
MSP -PG0UZE5TZ7W/_6.Z[K<)R='9RI&H^2-DC)5(;G:ERVXP*R\F9@T0ZI^]
M:VOL2'?XG@I3)D)@/0DN(:FO=X 68K->;3D5GM606&Y0;S8K[;8-YLMXMDIF
M=;;K:;G%:FVZY6^;'6Y'F09T-]#K3K:E(<;712:UI6E0 1U_,A??:\]_C U]
M\B&KP :00 5NO*?_ ')7'+XP.1'RWYN #H^                     !Q.>
M;^W-TT<_XX6726PMRVU_G_IW(H^7Z1PK6UK8SG*L>@Y+6V0\XQ#<<F')CVK7
M>&Y?CS4:<EF?-CWA4R# EQ(<N.EYMT 3:@ ?K6&_7O%KY9<GQJ[W+'\CQR[6
MZ_8_?K--D6V\62]VB8S<+5=[5<8;C,N!<K;/CMO,/M+2XTZA*DUI6E*@ K;>
M7BZUE@ZIW'/W?;9O%IM?-;0MEMUOVY84J8@+VGB;7@6VR[TQ:VIHVTJ+>'U(
MBY#%C4JBUWJM%5;8BS[>A0 Z+    :^MF=6#IH:9S[*M6;6YU\7L V-@UV?L
M.8X5E&X<.M618S>XR4*E6B]6R1<TR+?<HGB42ZRY1+C2^U*J452M* #X7[:W
MI'_K&N('^W#"?SH #8?K[8&$;7P?$MF:URJQYSK[/,?M>5X7F6,W!B[8]E&-
M7N(U/L]]LESBK<C7"UW.$\AUAYM54.-JHJE:TJ #[                  '
MSN7XEC.?XGE&"9K8[;D^&YKCM[Q++<:O,9N;9\AQG)+;)LU^L=UANTJU+MMV
MM4UV.^TJE4N-.*37X*@ D:==[H8;9Z4^ZKOF^!V:_9UP?V5D4Z3J'9[#$VZN
M:Y<N$I3\;3VV9U$.^JLJLC;U&;9<I"DQ\DA-T?9526B=$B #GT   !DSQ<YE
M\J.%&>HV9Q3WOL;1V855$]82\(OST2TY''@/^DQ;;F>*3$S,3SBRM2/P_0+Q
M!G0E*_RFJ@ [9.F_YS>BEV/6W4YU,E"5*CP*<E]"6954HI6J6J7#8^F')*UU
M2FG:[*GXS)K7L[$L62M?A !W*Z!Y$:.Y3ZNQS=7';:6&[AU;E;-7++F>$7AB
M[6QUYM#2Y5LGH1W)MDOUMJ\E$RW3FH\^$[7PWV6W*530 >S
M   B#=6+[TWJ6?7_ .9']XK8P ,   6N>BE]T?TY?J@:/_0FU@ V?@
M       @#@   W18QYA[K,X;C6/8AC/.C/+3C>*6.TXWC]K9P/2[S5MLEB@1
M[7:;>T[*UH_)=;AP(K;:5.+6XJB>U2JU[:@ _<_:0NMK_P >^P/]GVD/]UX
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ML:T5J/ =5VN:INC;UU1A6-6ZQ2+Y,32E.VX7Z9#<FR5?NK??6JOPU ![X
M      "(-U8OO3>I9]?_ )D?WBMC  P  !:YZ*7W1_3E^J!H_P#0FU@ V?@
M              GA^>+_ )U.G;\7_([](]0  X0P =_GD8__ '1/ZDW_ *N
M =_@         - /FCON*.<W]6;^^'Q] !(% !N^\M[]]KP(^,#8/R(;0 !T
MD^<BZ7M9$;"NJ9J/'.\[%]F]/\L6;;'<4XJ*JD>QZ<VY<N[^+HW$<HSB-Q?5
M7O5H[8VT([J7ET $_@ &\[R^?4]?Z8W/["\LS*_.6WC;O3U;IWD='?=>K:K1
MBUWNC:L9VB_&;H[3TS5&1OIGN/(:=D^I7KG&9IWI5>T 6)F7FI#33[#K;[#[
M:'F7F5I<:>:<31;;K3B*J0XVXA5*I52M:5I7MH ",3U]_ODNH3]8"\?D.P@
MU @ K]>5Q^XHX,_UF?[X?(( &_X       $7/KQ99*S3K$=0Z\3/&\6'R2S'
M$T>.ZEY?HN!-P,%@]U:6VJ49]"QQOPT=E:MM]U-:JK2JJ@#4F "N=Y4_$H6.
M=$#BO>(JFZOY]EG(W+;C1$>K*D38?(K9V"(2\Y5]WTIRMOPIBM'*):[$52CN
MU[G?6 .BH &.?(OEYQ>XB67',CY0;\U7H2PY?=)=DQ:[[3S&SX=;[_=X,2DZ
M9;;5)O$F,W,F1H:J.K0BM5)17MK\  ,3/MK>D?\ K&N('^W#"?SH !]M;TC_
M -8UQ _VX83^=  /MK>D?^L:X@?[<,)_.@ 'VUO2/_6-<0/]N&$_G0 &RNQW
MNT9+9;/D>/W*'>;#D%KM][LEWMSZ)5ONMHNL1F?;;E!DM54W(ASH;Z'6G$UJ
ME:%4K3X*@ _4                 !"&Y8?2FY*_'_N3Y1<C !X  "YQT]?H
M"<'?J?\ &CY%\* !F              ##_J%?0$YQ?4_Y+_(OFH (8X ,O\
MI[?3ZX/?6_XT_+/A0 +G(               (0W+#Z4W)7X_]R?*+D8 /
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MXU-_-7K3XO\ #?T<MH /0          2A/-X_?)9K\0&B?R%<P <P0
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M])O*&Z)JI2:T %4\           '"%YXO^:WIV?R_P"1_P"CNG@ 3Q
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MBLO1NZ, V'.AQE*0N]XW8LAA/9?C#M4=CGH>5XI6;;9%$52NK$M=$J2KLK0
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M&6:FV5:XL.1D&"9-6)W69#D=F<Q+@34(;;N5KE1Y24-5=4RV ,^P
M     1!NK%]Z;U+/K_\ ,C^\5L8 &   +7/12^Z/Z<OU0-'_ *$VL &S\
M          $ <           ';YY(;Z4_.#ZO^O?E%? !1\         !Q!>
M=Y^BSP>^/_8GR=1P 3A          ?U08,VYS8=MML.5<+C<)4># @08[LN;
M.FRW4,18<.*PAQ^3*DON)0VVA*EK6JE*4K6H *2_EA>@%EW$J3;^H9S5P]['
M.0M]QV; X\Z6O\.K%^T?C630)-MO^PL^A2&_'M6ULOQZ6Y;X5KK5#M@L\N4F
M:E4^96/:P!VK@           B#=6+[TWJ6?7_P"9']XK8P ,   6N>BE]T?T
MY?J@:/\ T)M8 -GX               )X?GB_P"=3IV_%_R._2/4  .$, '?
MYY&/_P!T3^I-_P"K@ '?X         #0#YH[[BCG-_5F_OA\?0 2!0 ;OO+>
M_?:\"/C V#\B&T  5XM[Z2UQR2TQM#06WL?CY1K+<&#Y%K_-;)(2UWI5BR6V
MOVV6]!?=:>]7WBW^-23!F(3XT*:RT^U5+C:%4 $3+J&\*-C=/+F+N_B5LMN0
M_<M798^QC&2N1ZL1,\UU>6T7G7N>VVM*> J/E&*38K[S;:ETAS:OQ'*T>CNI
M2 ,+  54O*E=4)/-+A$WQ:V=D#<WD)PKM=@PE*I\MNMXSG0+R';?JS*VVW5I
MD3Y&%1X-<9N3C:%^$B';GY#E7[A3O #@KZ^_WR74)^L!>/R'80 :@0 5^O*X
M_<4<&?ZS/]\/D$ #?\       "*/UKD+1U<.HTE:5(K7E]NY=**35-:H<S6Y
MN-JI2M*5[JT*HJE?W*TK2M  :OP 6!O*_P ST[H7<%GO18<3N0^1,/PH+'H[
M*_5_+3?,#TI;?>7WID[T;QI"^W\;(<6OLIWNR@ WY  X@O.\_19X/?'_ +$^
M3J. "<(       "[QQ-^BQQH^K_IKY.L< !D                  "$-RP^
ME-R5^/\ W)\HN1@ \  !<XZ>OT!.#OU/^-'R+X4 #,              &'_4
M*^@)SB^I_P E_D7S4 $,< &7_3V^GUP>^M_QI^6?"@ 7.0
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M35*E)JE=.RM:?" #ZX         '"%YXO^:WIV?R_P"1_P"CNG@ 3Q  9O\
M"'IP\SNH[E6<83PRTW[Y,GUOC]NRG-+9[P]5:\]36&ZW%5I@3O3=JYS@UON/
MCW!-6_"B.OO)_P I2*)^$ &Q_P#9<>NO_P #/]IGAY_^(( &CG9FMLYTWL;/
M-2;/QJX8;L?6.89'@.>8G=:,>LL;R_$;O+L.162:J*](BN2+9=H+K*EM..-+
MJCO(6I-:*J /AP 5=/+E]/+I20^'?'3GAQCTJG)=XYMAK<?,-H;EOWO+V5KC
M:N.U<QC9>+XRF1!M.)8(JUY5 G)AS[-9+3<+A:)3+KKBV'VT4 '4(
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M0A2DN@#K>ZUOW1_4:^J!O#]";H "*, #9]T4_O;^G+]<#1WZ<6H %KH
M      $VGSJ_*ZF<\K^,G#VQSU.VC06J;SM?-&8[JTL*S[=MTC0;5:[DQ55$
MNSL=P7 (<R.ON]B&<A71*JU4NE !Q.@ I4^2JXO(P/AQR8Y87:WI:O?(3<UI
MUOC4E]JBWEX!HJQR'?3K<\MOO1XMWSG8]VC24MK['G+.U5RE?";[ !VG@
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MERJO#3;\AEU4E2DM50 *TX             (@W5B^]-ZEGU_^9']XK8P ,
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M18-D8UA[<BU67&->*M&2,2T6^=:K+;+I-L<B,X\^\V_12@!U,
M   B#=6+[TWJ6?7_ .9']XK8P ,   6N>BE]T?TY?J@:/_0FU@ V?@
M         GA^>+_G4Z=OQ?\ ([](]0  X0P =_GD8_\ W1/ZDW_JX !W^
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M\Y"=E08<ER,I"G6&5U4VD >/@ N\<3?HL<:/J_Z:^3K'  9
M      A#<L/I3<E?C_W)\HN1@ \  !<XZ>OT!.#OU/\ C1\B^%  S
M       !A_U"OH"<XOJ?\E_D7S4 $,< &7_3V^GUP>^M_P :?EGPH %SD
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M2FE.RE*?!2@ /^OM">?7_'#R_P#^9;<__C4 #[0GGU_QP\O_ /F6W/\ ^-0
M8K7Z_7W*K[>LHRB]7;),ER2[7&_9%D5^N,R\7V_7V\3'KA=KU>KM<'I$^Z7:
MZ3Y#C\F2^XX\^\XI:U*4JM:@#\D %=KRN?*_YT72!T/:;K<O6.9\8KIDO&#*
MO$D>*^U;]>KA7?63:6%H2['APM0958(3?PK0M<-SNJIV5;; '0\
M#A"\\7_-;T[/Y?\ (_\ 1W3P )X@ .WSR0WTI^<'U?\ 7ORBO@ H^  F2^<4
MZ>Z]%<Q,%YT8+951];\N[2FP;&<A1*HM]DW_ *YM$*!(D2G6J(BPU;(UZQ"F
M1V^[XLJ?9[M(4I555[ !QP@ [9/)L]1A_5?(?9/3HV#>_#P'D;'N.T])HG2T
M-QK)O+"K"BN7V& T\XTVGWEZSLWCN5[5J]*Q>*TTWWI+B@ 4E
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M;JQ?>F]2SZ__ #(_O%;& !@  "UST4ONC^G+]4#1_P"A-K !L_
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M*9CUP<6EMR1(ME95$):DM54 -2(     *_7E<?N*.#/]9G^^'R" !O\ @
M    37?.N<:Y6&\Q>+G*BW6U36/[ST;=M6WN9'92IAS.M'Y4_<URKD\VFJF9
MUSPW:5KCQZ.UIXS-I7X7>\%WN@#BI !VU>2NYA6W7_)[DGPLRB[IB1^1& V3
M:NL(TR0PW'D;"TM6\-Y78+0RIQ,B1>LDUWE3US<2E*T^AXJXJM4=S\, 4C@
M      1!NK%]Z;U+/K_\R/[Q6Q@ 8   N\<3?HL<:/J_Z:^3K'  9
M            A#<L/I3<E?C_ -R?*+D8 /   7..GK] 3@[]3_C1\B^%  S
M             !A_U"OH"<XOJ?\ )?Y%\U !#' !E_T]OI]<'OK?\:?EGPH
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M       !!&VO_.ELK^7^8_I%<0 ?   O<:F_FKUI\7^&_HY;0 >@
M  E">;Q^^2S7X@-$_D*Y@ Y@@ 5>O*&_<VX7]8#>WY<M8 .GX
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MBW+@D.4\]6,WG6G;JY9,DMUICI[S+=RR?"<]K,DK52G?CXTBG>I5"4J %((
M        '"%YXO\ FMZ=G\O^1_Z.Z> !/$ !V^>2&^E/S@^K_KWY17P 4?
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M "U@ #6!UK?NC^HU]4#>'Z$W0 $48 &S[HI_>W].7ZX&COTXM0 +70
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MJO3>&W7-LRN]&TR)?J^VMI3&M=G@U<95=,BR"Y/,6^V0D*HY-N$IEA'X;B0
M:'^B[YCSCQU1KK>M*[/MUCXX\K&<DRF5@^MKG>FZXMMK 'K]=YF(LZWR"Z3?
M2+WLC&,/3%8R*TK0R_+D,NW*VM*AKD1;8 .DX     &K3K7\D<'XL=+#F]LG
M-Y\.+Z\X_P"Q=289;Y3E:.9!L?<V,W+6>#66+&:K25-[U^R5N3*0S^&U;XTA
MY54-M+<2 (J0 /4=':RN>Z]U:?TW96GG[SMK:.O]96EF.Y1F0]<\\RRTXK :
M8=5&FI:><E75%$JJR[1*JTKW%?Y-0!>G             !$&ZL7WIO4L^O\
M\R/[Q6Q@ 8   M<]%+[H_IR_5 T?^A-K !L_             ! '   !=XXF
M_18XT?5_TU\G6.  R                  !Q!>=Y^BSP>^/_8GR=1P 3A
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M7WIO4L^O_P R/[Q6Q@ 8   M<]%+[H_IR_5 T?\ H3:P ;/P
M   3P_/%_P ZG3M^+_D=^D>H  <(8 ._SR,?_NB?U)O_ %<  [_
M : ?-'?<4<YOZLW]\/CZ "0* #=]Y;W[[7@1\8&P?D0V@ "QT   #G-\S'TO
M5=1/@->,SUQCGK;DSQ);R+;NI$P8[C]ZR[$?5K#NW-4P6FN^Y+D9=C]EC7"W
MQT-K?D7NR0H[=4)D.]X 2.0     5^O*X_<4<&?ZS/\ ?#Y!  W_
M -!7F3N!$_GGTNMMVW"K&J][DXYRF.2.J8<2/X]UN[^ 6RZ-; Q.WI:I69+E
M9+K.YW9,.$U1:IEWCP440I5$=@ C^  ]SXR\B=G\2>0&H^2NF;NW9-FZ7SBR
MYUB4R2TJ3;WYMI?[95GO,-#C*I^/Y#;7'X%QC=]'I,&2ZU55*+[0 6GNG3U
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M=92\Y&U[E=R=:0M7AU?;157P4 !;F         !PA>>+_FMZ=G\O^1_Z.Z>
M!/$ !V^>2&^E/S@^K_KWY17P 4?    26O--=/KYE/4NRO9N'V5-MTMS/BW3
M?.%5BL,L6ZU[#>GL1=Y8DPEE##='HF:3VK[1"&TML0LDBLTJI3:Z@ YK  =W
M'DQ^HPWB^?;;Z9NP[QW+9LQR\[[XZUF/U5X>=X_88C&W\#@T<4ZZKU_@]AC9
M!$CMT;CQ_45T>5VNROA %$            $87K[_ 'R74)^L!>/R'80 :@0
M6.?+>?<E<"/Y ;"^7':( -WX .#CSLO#ZMWP3B7SNQZUJ<EX?>KUQCVC<&6T
MNNUQ_)T778VI'W^XFCT:VV6_6W*6%NK[S59-ZCH[4+6FCH GG  [\?)+</JN
M3.77/+(;6KPXS-DXLZLN+C:%-K?D*LVS]R+;HXFJT/1F6L.:9>;_ '4/R6ZU
M_P J@ * X -8'6M^Z/ZC7U0-X?H3=  11@ ;/NBG][?TY?K@:._3BU  M=
M        X-/.V\KT6[!>'?".QW15)>49%D_)G8UL9>HTXU:,7ASM::IK)0CM
M=E0;S=+_ )6ON+JEI+]J;7V+6E-6@!/2 !U'^43XO+WMU9++MJYP%2,5XEZA
MV!MU^2^U5RW.9KE$1G4>$6EZM&W*4N79GEPO$2BJHI1=C6NBN\A*%@"K2
M  #PWDYHO&N3O'+>_'/,$L^S.]-0[$U/>'GF/'] BY[BEUQKUJPBBD.-SK.Y
M<4RHSK:D.LR&4.-J2M*54 $*'-\-R+76:9?K[+[<Y:,LP7*+_AN46EZM*NVS
M(L8NLNR7NW.U3^#5R%<H+K:NSX.U( /EP 6Z^D[RO3S<Z<G$#DM(NBKQDF?:
M9QN#L.>X]1]]_:V"4?U[M9Q]7^6E3VP\6N3B*+I1=6EI57M[>VH V&@
M  U =?C[FWJ$_$!=_P NV$ $88 &W[H$??)=/;ZP%G_(=^ !9Z     !*R\U
MOTO*<+N;:N5&KL>5 X]<TKE>\T=:M\5:+1@O()E5)VT\5[R5OHBQ<W>DTRFW
MI75I*WI]QC1FDQ[?3L '*H   "MUY3_[DKCE\8'(CY;\W !T?
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M+M2*,VVFY<&BN1;5:]Y8O;$I;CID29#[,3*(43M9M]X<1(0W&B7&'': '2,
M                  ":?YN#J[.;_P!VIZ;6BLH\?3'';)*3N1%TM#Z:1L]Y
M"VI4B+["/28[SE)F/Z4:=7'E,*JVE64O2T/M5<M<5T '&+;+G<K)<K?>;-<)
MUHO%HG1+G:KK;)<B!<K9<H$AN5!N%OG17&I4*="E-)<:=;4EQMQ-%)K2M*5
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ML<+7N-ON.7"DGNI<]*I1OL[:I4 #J2         !Q!>=Y^BSP>^/_8GR=1P
M3A  =OGDAOI3\X/J_P"O?E%? !1\   !)L\U1T^E\,^I7D^X,1L_H.F>;,>Z
M[WQ9R+%?;M]JVDN<Q%WOBWI+OXI^X.9G.:R526NZVQ%RAAE-/Q50 <S0 .ZK
MR9'457B6S-O=-?8V1);Q_:3-QWEQUCW&17LC;&QNU,,;9PBU5=4XM:LKP:UQ
MKZQ&1X;#%<>N#OPNRU=X 43@           1!NK%]Z;U+/K_ /,C^\5L8 &
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M&         !&%Z^_WR74)^L!>/R'80 :@0 6.?+>?<E<"/Y ;"^7':( -WX
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MT<OTZXLR(FK-_P!($.C$&+LJ/:HDN7CF<,M,-LQLGA1WW'6$^!<(TM*8[\,
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MYPI"4/P[A;9\9QEYI::+;<15-:4K2H /QP 5^O*X_<4<&?ZS/]\/D$ #?\
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M &;]AO4=K]C_ &.]6>R?LUZ&SZE]FO4G^9_4?J_P_1?1?WOX/=\/\'L !](
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MF>P?M9[?^N_7?M_?_;KTGWF_QP\/VP],\/TC\7X?9X7XON@ VA@
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MY/ [YNWS,.,'S1_6GS8O<G@'N&]=^T?K?W6^H(GL?ZR]K_XT>F>J/#\3T_\
M?7>_[3\+M !EF             "<'_@EOZ0']M\ #_!+?T@/[;X '^"6_I ?
MVWP /\$M_2 _MO@ ?X);^D!_;?  _P $M_2 _MO@ VS]%?\ 9I_GQ6'[+WWL
M?.L]V^P_5'M?\YGU-[$^KXGMGW_>E_%/TCT+P_#[_P"/[?\ L_A[0 =BH
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MWNO]-[&?6O@>[[_,GM!XO=]8^+^__2.WTG\;W@ 90
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MX-O_ .0#_OP !_@V_P#Y /\ OP !_@V__D _[\  ?X-O_P"0#_OP !_@V_\
MY /^_  *&O3S]P/S&>)WS5O:CYMWN'US[D/;;TGVN]VGL["]D_:/TS]]>N/5
M7A^/XGX??[>T &8X     )J6[OV0WWT;=]XOS\/>#[T,^]N_5/MIZJ]LO:N[
M>T_JSPOQ?J_UWX_@]W\'P^SL^  'F'^#;_\ D _[\  I"<6?=G\V+CE[EO7'
MN<]P^H?=-[0^+Z_]V?N^Q[V$]>>/^/\ 7'LMZ+Z3W_P_&[W;\( />
$ #__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
